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ABSTRACT
Group B streptococcus (GBS) is the leading cause of life-threatening bacterial
infections during the first three months of life. GBS is also a frequent cause of maternal
postpartum infections. Both types of infections stem from maternal vaginal and/or rectal
colonization with GBS in the perinatal period.

Limited information is available

concerning how the colonization process occurs and what role the host immune system
may play in the establishment of persistent colonization by GBS.

The complex

interactions between the immune system and GBS normally should end in clearance of
the bacteria. However, since colonization by GBS occurs in a large number of women it
can be surmised that the immune defenses are not functioning in a manner consistent with
a protective response or that GBS is in some fashion undermining them. Investigations
examining interactions between GBS and components of the innate immune system
support this hypothesis. Measurement of phagocytosis and respiratory burst capacities
revealed that monocytes, in particular, from these women internalize larger quantities of
bacteria while the antimicrobial superoxide is shunted to an extracellular location. This
data indicated that phagocytes from colonized women might become a protective niche
for GBS upon engulfment. Additional data also showed that these same women (GBScolonized) had significantly increased levels of mannose binding lectin (MBL) in their
sera and that high levels of MBL significantly enhanced phagocytic engulfment of GBS.
While these data support the idea that the host immune system is not functioning as it
normally should to prevent infection and colonization, other data provided evidence that
GBS is capable of using components of the immune response to its own benefit. GBS
bound interleukin-6 (IL-6) and used the biologically active pro-inflammatory cytokine to

ix

enhance its growth and the expression of at least one virulence factor, the C5a-ase.
GroEL, a protein implicated in pathogenesis of a number of other bacterial species, was
also increased by IL-6 exposure to GBS. Understanding how the immune system and
GBS interacts is key to elucidating the mechanisms that underlie the colonization and
infection processes as well as may aid in the identification of targets for potential
treatment and prevention strategies.

x

CHAPTER 1. GENERAL INTRODUCTION
INTRODUCTION
Group B streptococcus was originally identified as a cause of bovine mastitis in
the 1800s. The first documented case of human group B streptococcus (GBS) infection
was recorded in 1938 (Weisman et al, 1992). By the 1970s, GBS was recognized as a
major cause of life-threatening neonatal bacterial infections.
During this period GBS research has focused primarily on prevention and
treatment strategies for neonatal GBS disease. While some attention has been paid to
phagocytosis of GBS, epithelial cell invasion by the bacteria, and specific virulence
factors, many areas of immunity to GBS remain relatively underexplored. More detailed
knowledge of how the immune system and GBS interact with one another will aid in the
development of models of GBS pathogenesis as well as identify potential targets for
future therapeutic and preventative measures.
The aim of this study was to examine the interactions between group B
streptococcus and components of the innate immune system including engulfment and
respiratory burst activity by phagocytes, mannose binding lectin gene polymorphisms and
opsonic capacity, and the effects of pro-inflammatory cytokines effects on GBS growth
and virulence. These investigations were designed to test the hypothesis that interactions
between GBS and the innate immune system may contribute to the GBS colonization
process, or at least does respond in a way that would prevent colonization.
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LITERATURE REVIEW
GBS Microbiology
Streptococcus agalactiae, more commonly referred to as group B streptococcus
(GBS),

is

a

gram-positive,

facultative

anaerobic

bacterium

of

the

family

Streptococcaceae. GBS can be found as a component of the normal flora of the adult
gastrointestinal tract, urogenital tract, and upper respiratory tract.
Phenotypically GBS colonies appear flat, grayish-white and glistening on solid
media. Gram stain smears of GBS isolates reveal chains or pairs of cocci.
Identification of GBS from individuals suspected of GBS infection is
accomplished by culture of the bacterium from normally sterile body sites (blood, urine,
cerebrospinal fluid). Presumptive identification of GBS is based on colony morphology,
presence of β-hemolysis, hippurate hydrolysis, and a positive CAMP test. Confirmation
of GBS identification relies on detection of the group B antigen by latex agglutination.
GBS may be categorized into serotypes based on the capsule polysaccharide
composition. To date there have been at least 9 different GBS serotypes (Ia, Ib, II, III,
IV, V, VI, VII, and VIII) identified. Serotypes Ia, Ib, II, III, and V are most commonly
isolated and most often associated with GBS disease, although all of the serotypes are
capable of causing infection (Harrison et al, 1998; Andrews et al, 2000; Tyrell et al,
2000; Davies et al, 2001).
Risk Factors
In 1996-7 the Centers for Disease Control, the American College of Obstetricians
and Gynecologists and the American Academy of Pediatrics released guidelines for
identifying pregnant women at risk for having an infant with GBS disease (Schuchat et
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al, 1996; ACOG, 1996; AAP, 1997). Delivery of an infant with GBS disease in a
previous pregnancy is one of the six criteria.

Premature rupture of the amniotic

membrane, prolonged rupture of the amniotic membrane, intrapartum fever, GBS
bacteruria, and GBS colonization late in pregnancy are the other risk factors.
In adults, risk factors for GBS infection differ from those for neonatal disease. In
pregnant women, prolonged rupture of the amniotic membranes, intrauterine monitoring,
and multiple vaginal exams during labor are risk factors for peripartum infections
(Schuchat et al, 1998). Having an underlying condition like diabetes mellitus, cardiac
disease, or cancer; immunosuppression due to HIV infection or immunosuppressive
therapy; or being elderly increase the risk of acquiring GBS disease (Michel, 1990).
Race also appears to be a risk factor for GBS disease, as there is a higher
colonization rate in African American women and a higher neonatal infection rate in
African American infants (Schuchat et al, 1998). This association between African
American race and GBS disease may reflect the increased incidence of low birth weight
and premature infants in this population.
Maternal Screening
Because prophylactic antibiotic treatment given during labor to women identified
as “at risk” has been shown to dramatically decrease transmission to the neonate (Boyer
et al, 1986; Gilson et al, 2000), many obstetricians perform GBS screening cultures at 3537 weeks during pregnancy. Typically, swabs are taken from the vagina of the patient.
However, cultures taken from both the vagina and rectum increase the accuracy in
identifying women that carry GBS (Quinlan et al, 2000). Most often swabs are taken by
the obstetrician or nurse, but studies by Mercer et al (1995) show that specimens
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collected by the women themselves are equally accurate for determining GBS
colonization as those collected by the clinical staff.
In the clinical microbiology laboratory, the anogenital swabs are inoculated into a
selective medium.

Routinely Lim broth or Todd-Hewitt Broth supplemented with

gentamicin and nalidixic acid are used to inhibit growth of other normal flora (Dunne et
al, 1998).

The selective media culture is then streaked onto sheep’s blood agar.

Presumptive identification of GBS is based on colony morphology and presence of βhemolysis. GBS confirmation involves agglutination with anti-GBS antibody-coated
latex beads (Michel, 1990).
GBS Disease
In Neonates
In infants, GBS disease is categorized based on the time of the appearance of
symptoms. Early-onset neonatal disease, which accounts for 70-80% of all neonatal GBS
disease, occurs in the first seven days following birth (Schrag et al, 2000; Spellerberg,
2000). Incidence of early-onset disease in the United States was 0.5-2 per 1000 live
births with a fatality rate of 4-5% in the 1990s (Schrag et al, 2000). Transmission of
GBS resulting in early-onset disease can occur by aspiration of contaminated amniotic
fluid during parturition or in utero by GBS that have crossed the intact amniotic
membranes.

The primary syndromes seen in early-onset neonatal GBS disease are

bacteremia, pneumonia, and meningitis (Ferrieri, 1985; Schrag et al, 2000).
Meningitis and bacteremia due to GBS infection in an infant between 7 days and
3 months of age is considered late-onset neonatal GBS disease. Incidence of late-onset
disease in the United States was 0.3-0.5 per 1000 live births with a fatality rate of
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approximately 3% in the 1990s (Schrag et al, 2000). The mode of transmission of lateonset neonatal GBS disease is unclear, but is believed to be by a community or
nosocomial route.
Pneumonia associated with GBS disease presents with signs of respiratory distress
within the first 24-48 hours following delivery. Infants with GBS pneumonia have
tachypnea, cyanosis, apnea, acidosis, and leukopenia (Ferrieri, 1985). Because of the
similarity of symptoms, GBS pneumonia is often misdiagnosed as hyaline membrane
disease (Michel, 1990).
Although meningitis is seen with early-onset GBS disease, the majority of cases
are associated with late-onset disease. Signs of GBS meningitis include lethargy, fever,
vomiting, and seizures (Michel, 1990).

GBS enter the central nervous system by

invading brain microvascular endothelial cells (Nizet et al, 1997). This invasion leads to
cellular injury including necrosis in the cerebral cortex and apoptosis in the dentate gyrus
of the hippocampus (Kim et al, 1995; Leib et al, 1996). This damage, due to the
inflammatory response induced by GBS, can lead to permanent neurologic deficits in
infants surviving GBS meningitis (Michel, 1990).
Septic shock results from an overwhelming inflammatory response to GBS
bacteremia. GBS sepsis is characterized by cardiovascular collapse, diffuse intravascular
coagulation, and multiorgan failure (Michel, 1990; Spellerberg, 2000). Many of these
alterations are mediated by proinflammatory cytokines, including interleukin-1 (IL-1),
interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), or by other inflammatory
molecules induced by these cytokines (Vallejo et al, 1996; von Hunolstein et al, 1997;
Kwak et al, 2000; Berner et al, 2001).
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In Pregnant Women
In the 1990s, GBS infections in pregnant women accounted for 6-15% of all
invasive GBS disease (Schuchat et al, 1998; Schrag, 2000). The majority of these
infections were bacteremia, meningitis, osteomyelitis, and endocarditis (Schuchat et al,
1998). GBS also causes urinary tract infections, postsurgical infections, amnionitis, and
endometritis in pregnant women (Schuchat et al, 1998). Late term spontaneous abortion
and stillbirth have been linked with GBS in the genital tracts of pregnant women
(Daugaard et al, 1988).
In Nonpregnant Adults
The mean age of adults with GBS disease is approximately 60 years and the
fatality rate is the highest for persons over 65 years of age. Interestingly, underlying
conditions like diabetes and cancer only increase the risk of GBS disease in the over fifty
population by 4-6 fold (Schuchat et al, 1998). However, in individuals 20-64 years old
diabetes increases risk by 11-30 fold and cancer increases risk by 25 fold in individuals
20-49 years old (Schuchat et al, 1998). The majority of GBS disease in nonpregnant
adults is pneumonia, bacteremia, and soft tissue infections (cellulitis, osteomyelitis, septic
arthritis, wound infections) (Schuchat et al, 1998).
Treatment
Current treatment for GBS disease relies on GBS’s continued susceptibility to
penicillin G and ampicillin. Routinely, high doses of ampicillin with an aminoglycoside
are given intravenously. For patients with a known penicillin allergy, erythromycin,
clindamycin, or chloramphenicol have been used as substitutes (Michel, 1990). However,
in recent years a significant increase in the number of GBS isolates resistant to
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erythromycin and clindamycin has been reported (Morales et al, 1999; Lin et al, 2000; De
Azavedo et al, 2001; Murdoch et al, 2001). Mechanical ventilation, seizure control, and
blood transfusions may be required in addition to antibiotic therapy (Michel, 1990).
Prevention
Intrapartum antibiotic therapy is used as a measure for prevention of early-onset
GBS disease. However, it does not protect against late-onset neonatal or adult GBS
disease. Vaccination against GBS is the best solution. The ideal GBS vaccine would
elicit both systemic and mucosal responses as well as generate antibodies capable of
passing through the placenta to the fetus. Initial attempts at designing a vaccine against
the GBS type III capsule polysaccharide did not produce a sufficient response as only
40% of the women vaccinated generated the antibody titers necessary for protection
(Baker et al, 1988). More recent attempts using protein carrier conjugates, like tetanus
toxoid (Kasper et al, 1996; Wessels et al, 1998; Paoletti et al, 2001) and cholera toxin B
subunit (Shen et al, 2000; Shen et al, 2001) show promise, as the vaccines have proven
efficacious in the maternal immunization-neonatal challenge mouse model.

These

studies also demonstrate that the route of administration impacts the type of antibody
response. Shen et al (2000) provide evidence that intranasal immunization elicits IgG
and IgA responses in the lung and IgG in the serum, oral immunization elicits IgG and
IgA in the intestines and IgG in the serum, vaginal immunization elicits IgA in the vagina
and IgG in the serum, and rectal immunization elicits IgA in the rectum, vagina, and
intestines and IgG in the serum.
Other recent vaccine designs are focusing on creating a multivalent vaccine that
includes capsule polysaccharide antigens from the most commonly isolated GBS
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serotypes or vaccines that include the known immunogenic GBS surface proteins.
Epidemiologic studies of GBS serotype distribution in large medical centers indicate that
a vaccine against types Ia, Ib, II, III, and V would protect 80-95% of the population
(Harrison et al, 1998; Andrews et al, 2000; Tyrell et al, 2000; Davies et al, 2001). A
study in a small community hospital in Huntington, WV, confirms that this type of
multivalent GBS vaccine would provide protection against the most common serotypes in
this setting as well (Smith et al, in submission, 2002). Because they are expressed on the
majority of GBS isolates, inclusion of the α-C and Rib proteins, two surface-expressed
proteins thought to function as virulence factors, in a vaccine would alleviate the need for
a carrier protein as well as elicit a protective response to additional GBS antigens
(Larsson et al, 1996; Gravekamp et al, 1999).
Innate Immunity
The host innate immune response provides the earliest line of defense against
colonization and infection as well as provides signals that direct the adaptive response to
follow. Innate immunity is mediated by a series of pathogen-nonspecific interactions
with serum proteins and phagocytes.
Complement System Activation
Complement, a system of serum proteins produced mainly by the liver, is
activated by a cascade of proteolytic cleavages. Products from these cleavages mediate a
variety of functions that initiate an inflammatory response and enhance clearance of
microbes. C3a, C4a, and C5a promote chemotaxis of phagocytes to the site of infection
as well as induce the release of inflammatory mediators by granulocytes. C3b acts as an
opsonin to enhance phagocytosis.
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The complement system may be activated by three pathways.

The classical

pathway of activation requires microbe-specific antibody, which interacts with C1q and
its associated serine proteases, C1r and C1s. This complex cleaves other components of
the complement system leading to the formation of the C3 convertase, which cleaves C3
creating the C3b opsonic product.
The alternative pathway of complement activation results from spontaneous
hydrolysis of C3 to C3b that then deposits on the microbial cell surface. This C3b
interacts with additional complement proteins to generate a complex with C3 convertase
activity, which amplifies the production of C3b and increases the availability of opsonin.
The final pathway of complement activation is the lectin pathway. Lectins bind to
carbohydrates on the microbe’s surface and initiate a proteolytic cleavage cascade in a
manner similar to the classical pathway.
The best-characterized member of the lectin family is mannose binding lectin
(MBL). MBL is a Ca2+-dependent lectin composed of oligomers of trimeric protein
subunits.

Its carboxyl-terminal carbohydrate binding domain recognizes N-

acetylglucosamine, mannose, N-acetylmannosamine, fucose, maltose, or glucose on the
surface of various bacterial, viral, and fungal organisms (Holmskov et al, 1994). MBL
also contains a collagen helix-like domain that is required for oligomerization and
complement activation (Kurata et al, 1993; Wallis et al, 1999; Heise et al, 2000). The
MBL collagenous domain interacts with the mannose binding lectin-associated serine
proteases (MASPs) (Thiel et al, 2000; Thielens et al, 2001). The MBL-MASP complex
activates C2 and C4 to form the C3 convertase, which in turn produces C3b to enhance
phagocytosis (Gadjeva et al, 2001).
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In addition to activating the complement system, MBL itself acts directly as an
opsonin. MBL bound to one of its carbohydrate ligands on a microbial cell surface
interacts with a phagocyte surface receptor triggering engulfment (Turner, 1996).
Phagocytosis
Phagocytosis is a multi-step process mediated primarily by monocytes and
neutrophils.

Phagocytosis is initiated when receptors on the phagocyte cell surface

recognize their ligands. The ligands for these phagocyte receptors range from microbial
cell wall components (polysaccharides, lipoteichoic acid, lipoproteins) to complement
proteins to immunoglobulins (Unanue, 2002). Although these receptors each engage
different microbial components, several working together may constitute the functional
recognition unit (Zhou et al, 1993; Zhou et al, 1994; Petty et al, 1996).
Receptors that recognize patterns common to microorganisms and those that
recognize complement-opsonized microorganisms are crucial to the process of
phagocytosis. An example of a family of receptors that recognize various components on
the microbe’s surface is the Toll-like receptors (TLRs). Different members of the TLR
family recognize different types of microorganisms. For example, TLR-4 recognizes
gram-negative bacteria while TLR-2 recognizes gram-positive bacteria and yeasts
(Unanue, 2002). Upon interacting with their specific ligands, TLRs initiate a series of
signaling events leading to phagocyte activation.
Complement-opsonized microbes interact with several complement receptors on
the phagocyte depending on which complement component has been deposited on the
organism’s surface.

Complement receptor 1 (CR1) ligands include C3b and C4b

(Fallman et al, 1993).
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The primary ligand for complement receptor 3 (CR3) and

complement receptor 4 (CR4) is the inactivated C3 cleavage product designated iC3b
(Arnaout, 1990). The receptor that recognizes the C1q component also acts as the
receptor for mannose binding lectin (Holmskov et al, 1994).

Engagement of these

receptors leads to engulfment of the microbe and in some cases to activation of additional
pathways that impact the immune response.
Interaction between the microbe and the phagocyte’s receptor(s) results in
internalization of the microbe in a phagosome. Phagosomal maturation involves fusion
with lysosomes and creation of a microbicidal environment, including low pH, lytic
enzymes, nutrient deprivation, and reactive metabolites. The introduction of several lytic
enzymes and antimicrobial peptides into the phagosome occurs upon fusion with the
lysosome. These degradative proteins include proteases, acid hydrolases, lysozyme, and
the defensins (Brown et al, 2002).
Nutrient deprivation, particularly limitation of iron, acts as a microbicidal
mechanism.

Iron limitation occurs not only by keeping the microbe within the

phagosome, but also by a protein called natural resistance-associated protein 1 (Nramp1).
Nramp1 is relocated from the cytoplasm to the phagosomal membrane after engulfment
of the microorganism and functions to remove iron from the phagosome (Brown et al,
2002).
As phagocytosis proceeds, reactive oxygen and nitrogen metabolites are generated
in an effort to kill the engulfed microbe. A phagosome membrane-bound NADPH
oxidase converts O2 to superoxide. The superoxide is then converted to other highly
bactericidal compounds, including hydroxyl radicals, hydrogen peroxide, and
hypochlorous acid (Brown et al, 2002).
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The reactive nitrogen species nitric oxide (NO) is produced by inducible nitric
oxide synthase from L-arginine. Upon interaction with superoxide another toxic nitrogen
metabolite, peroxynitrite, is formed. Reactive nitrogen species have been shown to
control a number of infectious diseases in mouse models (Brown et al, 2002). However,
induction of sufficiently high levels of NO by human phagocytes has yet to be
demonstrated.
The anticipated outcomes of the phagocytic process are destruction of the
engulfed microorganism, activation of additional immune effector mechanisms, and
antigen presentation leading to an adaptive (antigen-specific) immune response.
A number of diseases are associated with deficiencies of certain components of
the phagocytic machinery.

Deficiencies in components of the classical pathway

predispose individuals to infections with pyogenic bacteria, while C3 deficiencies are
associated with severe, recurrent bacterial infections. Deficiencies in mannose binding
lectin are associated with a multitude of serious, recurrent infections as well as some
autoimmune disorders (Holmskov et al, 1994; Epstein et al, 1996; Turner, 1996). A
deficiency in the subunits of CR3 produces phagocytes defective in adhesion,
chemotaxis, and phagocytosis leaving afflicted individuals susceptible to potentially fatal
bacterial infections (Arnaout, 1990). A deficiency in the NADPH oxidase complex that
generates reactive oxygen species results in chronic granulomatous disease and impaired
killing of microbes within the phagosome (Malech et al, 1987).

These examples

underscore the importance of the phagocytic machinery in providing early protection
against infection and/or colonization.
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Immunity to GBS
Antibody- and/or complement-mediated phagocytosis have been shown to be the
most effective immune mechanisms for prevention of GBS infection (Baker et al, 1976;
Shigeoka et al, 1978; Shigeoka et al, 1983; Kallman et al, 1998; Campbell et al, 2000).
Antibodies to the GBS serotype-specific capsule polysaccharide are highly effective in
mediating uptake of GBS as well as inducing respiratory burst activity of phagocytic cells
(Shigeoka et al, 1978; Kallman, 1998). Antibodies to other GBS surface antigens, like
the C and Rib proteins, elicit a protective response in murine models of GBS infection
(Michel et al, 1991; Madoff et al, 1992).
In addition to GBS-specific antibodies, complement is required for elimination of
GBS. Shigeoka et al (1978) demonstrate that activation of the classical complement
pathway is necessary for phagocytosis of serotypes Ia and II GBS, but not for serotype III
GBS. Shigeoka et al (1978) also demonstrate that serotype III GBS fail to activate the
alternative complement pathway. The inability of type III GBS to activate the alternative
complement cascade is attributed to the high sialic acid content of its capsule (Marques et
al, 1992).
In the absence of opsonins, such as GBS-specific antibodies and complement,
phagocytic engulfment of GBS may occur via CR3.

Uptake of GBS by murine

macrophages is inhibited by anti-CR3 monoclonal antibodies (Antal et al, 1992).
Cuzzola et al (2000) report that anti-CR3 monoclonal antibodies inhibit secretion of
tumor necrosis factor-α, one of the major cytokines produced during GBS infection, in
response to GBS. Albanyan et al (2000) demonstrate that GBS interact with a lectin-like
site on CR3 in the absence of opsonization. The GBS ligand for CR3 has yet to be
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characterized, but may in fact be the group specific polysaccharide according to Cuzzola
et al (2000).
Following

internalization

in

murine

macrophages,

GBS

may

survive

intracellularly for 24-48 hours (Valentin-Weigand et al, 1996; Cornacchione et al, 1998).
This intracellular survival may be due in part to GBS’s ability to inhibit the protein
kinase C signaling pathway which leads to macrophage activation (Cornacchione et al,
1998).
Phagocytosis not only leads to microbial destruction but also to production of
cytokines. Cytokines are pleiotropic signaling molecules produced by many host cell
types.

The functions of cytokines include initiation of inflammation, activation of

effector cells and induction of the adaptive immune response. Although cytokines help
control the outcome of the immune response to a microbe, overproduction can actually
result in disease.

GBS septic shock is caused by an overwhelming production of

cytokines with pro-inflammatory properties. Several studies provide evidence that tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) are produced
in response to GBS or antigens derived from GBS and that these cytokines are key
mediators in the development of neonatal GBS sepsis (De Bont et al, 1993; Williams et
al, 1993; Peat et al, 1994; Vallejo et al, 1996; Von Hunolstein et al, 1997; Kwak et al,
2000; Berner et al, 2001). De Bont et al (1993) and Berner et al (2001) also report that
infants with GBS sepsis have elevated levels of these pro-inflammatory cytokines. Tissi
et al (1999) observe high concentrations of IL-1β and IL-6 in the joints of mice with
group B streptococcal arthritis. Reisenberger et al (1997) report that human amnion cells
secrete IL-6 and IL-8 in response to GBS.
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GBS Virulence Factors
Colonization and infection by a bacterium is related to its ability to survive within
the host environment and avoid the host’s immune system. Those bacterial products that
function in such a capacity are referred to as virulence factors.
Capsule
The capsule is considered the major GBS virulence factor. GBS isolates can be
categorized into serotypes (Ia, Ib, II-VIII) based on their capsule polysaccharides. The
GBS capsule consists of glucose, galactose, N-acetylglucosamine, and sialic acid with
each serotype differing in monosaccharide ratios and linkages (Rubens et al, 1990).
Serotype VIII differs in that N-acetylglucosamine is replaced by rhamnose and serotype
VI completely lacks N-acetylglucosamine (Spellerberg, 2000). Serotypes Ia, Ib, and III
possess sialic acid as the terminal sugar in the capsule polysaccharide.
A 15.5kb region of the GBS chromosome encodes the 16 genes for the capsule
synthesis operon (cps). cpsA, B, C, and D function in determination of polysaccharide
chain length. cpsE and F are structural genes for monosaccharide synthesis, while cpsG,
I, J, and K are structural genes for synthesis of the oligosaccharides from activated
monosaccharides. cpsL, neuB, neuC, and neuA function in transport and sialic acid
biosynthesis. cpsH is the capsule polysaccharide polymerase, which confers serotype
specificity. Upstream of cpsA is cpsY, which acts as a transcriptional regulator for the
cps operon (Chaffin et al, 2000).
All serotypes are capable of causing invasive GBS disease, but 50-60% of all
neonatal disease is due to infection with serotype III isolates (Ferrieri, 1990). Because of
the association of serotype III with the majority of neonatal GBS infections, type III
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isolates have been used primarily to investigate the role of the capsule in GBS
pathogenesis.
Serotype III GBS treated with neuraminidase to remove sialic acid are more
susceptible to serum antibody opsonization and have decreased virulence (Shigeoka et al,
1983). Additional studies by Rubens et al (1987) and Wessels et al (1989) using asialo
and unencapsulated serotype III mutants generated by transposon mutagenesis
demonstrate that the loss of capsule sialic acid leads to avirulence in a neonatal rat model
of GBS sepsis. These studies emphasize the critical role the capsule, in particular the
sialic acid, plays in GBS pathogenesis.
Bacterial capsules protect the microbe from the host’s immune system response,
particularly phagocytosis. Phagocytic killing of GBS is most efficient when serotypespecific antibody is present (Shigeoka et al, 1978). However, most women do not
possess specific antibody titers high enough to be protective (Vogel et al, 1980).
In the absence of serotype-specific antibody, activation of the alternative
complement pathway should facilitate clearance of GBS. However, GBS serotype III
strains fail to activate the alternative complement pathway (Marques et al, 1992). GBS
inhibition of the alternative complement cascade is due to the capsule’s sialic acid, which
alters the affinity of the C3b fragment for regulatory components and ultimately limits
the C3 deposited on the surface (Marques et al, 1992).
Hemolysin/Cytolysin
One of the most common presumptive tests for identification of GBS is βhemolysis. Despite the fact that the β-hemolysin is produced by approximately 99% of
all GBS strains (Rubens et al, 1990), characterization of the molecule has proven
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difficult. The hemolysin appears to be unstable when extracted from the cell unless a
high molecular weight carrier (albumin, starch, Tween 80) is present (Marchlewicz et al,
1980; Dal et al, 1983). Certain general characteristics including protease sensitivity
(Marchlewicz et al, 1980; Dal et al, 1983) and inhibition of hemolytic activity by
phospholipids (Tapsall et al, 1991) vary depending on the carrier used in hemolysin
preparation.
Due to the difficulties encountered in attempts at biochemical characterization of
the GBS hemolysin, genetic identification has been recently undertaken. The GBS βhemolysin is coded for by a 13 gene operon designated cyl. Spellerberg et al (1999)
identified eight genes in the cyl locus by transposon mutagenesis. cylA and cylB encode
an ABC transporter. cylD, cylG, and cylZ function in fatty acid synthesis while acpC
encodes an acyl carrier protein. cylX and cylE functions were undetermined. Pritzlaff et
al (2001) identify additional cyl genes by selecting E. coli DH5α colonies that gained βhemolysis activity upon transformation with plasmids containing fragments of the GBS
chromosome. cylF has homology with an aminomethyltransferase; cylH and cylI have
homology with 3-ketoacyl-ACP synthases; cylJ has homology with a glycosyltransferase;
and cylK has no known homology. In addition to extending Spellerberg’s work (1999)
by identifying 5 additional genes in the cyl operon, Pritzlaff et al (2001) demonstrate that
the cylE gene, while having no known homologs, is sufficient for a β-hemolytic
phenotype. The sequence of cylE does not display any motifs similar to known bacterial
toxins, indicating that the GBS β-hemolysin may possess a novel mechanism of action.
Electron microscopy indicates that the GBS β-hemolysin acts as a pore-forming
toxin. Wild-type and hyper-hemolytic GBS strains cause membrane disruption and cell
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swelling in A549 lung epithelial cells while nonhemolytic GBS did not cause injury
(Nizet et al, 1996). Hemolytic activity has also been correlated with damage to McCoy
cells (Tapsall et al, 1991), human brain microvascular endothelial cells (Nizet et al,
1997), mouse peritoneal macrophages, and human macrophages (Fettucciari et al, 2000).
The damage to murine and human macrophages leads to apoptosis. Fettucciari et al
(2000) propose that the GBS β-hemolysin creates disruptions in the macrophage
membrane, which leads to a Ca2+ influx and the induction of a caspase-independent
pathway of apoptosis. This may represent another GBS mechanism for circumventing
the host immune response.
C5a-ase
Neonatal GBS infections often show little infiltration of neutrophils at the site of
infection (Hemming et al, 1976). Hill and colleagues (1988) describe inactivation of C5a
by GBS and hypothesized that the lack of neutrophil accumulation in the inflammatory
foci in GBS infections is due to a C5a-ase enzyme similar to that of Streptococcus
pyogenes. GBS inactivation of the chemoattractant C5a occurs by proteolytic cleavage of
C5a between histadine 67 and lysine 68 thereby disrupting the neutrophil receptor
binding site (Bohnsack et al, 1991). The C5a-ase gene, designated scpB, was cloned and
characterized by Chmouryguima and colleagues in 1996. This 126-kilodalton serine
proteinase inactivates C5a from humans, monkeys, and cows, but not C5a from rodents,
sheep, or pigs (Bohnsack et al, 1997). Bohnsack et al (1997) also demonstrate that C5deficient mice reconstituted with human C5 and infected with C5a-ase-positive GBS had
decreased neutrophil infiltration compared to those infected with C5a-ase-negative GBS.
This study implies that the GBS C5a-ase is in part responsible for the diminished immune
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response to GBS in infants because of the reduced numbers of cells at the site of infection
that are available for clearance of GBS.
Hyaluronate lyase
Since many neonates with life-threatening GBS infections present with symptoms
within hours after birth, it is likely that infection occurred in utero. The main barrier to in
utero infection is the amniotic membrane, which is rich in hyaluronic acid. Hyaluronic
acid is also a major component of connective tissue. Hyaluronate lyases are considered
spreading factors because of their ability to cleave hyaluronic acid between N-acetyl-β-D
glucosamine and D-glucuronic acid residues (Pritchard et al, 1993; Pritchard et al, 1994).
The GBS hyaluronate lyase, originally believed to be a neuraminidase (Milligan et al,
1978; Pritchard et al, 1993), is produced in high amounts by GBS isolated from infected
infants (Milligan et al, 1978). Of all the GBS serotypes, type III strains were most
frequently high producers of hyaluronate lyase (Milligan et al, 1978; Kjems et al, 1980).
Although the exact role of the GBS hyaluronate lyase has not been elucidated,
Spellerberg (2000) proposes that it might play a role in allowing GBS to pass through the
amniotic membrane as well as degrade cellular basement membrane to facilitate
dissemination to other sites.
C protein
Between 40 and 60% of GBS strains have C protein antigens on their surface
(Johnson et al, 1984; Hickman et al, 1999). Serotypes Ia, Ib, and II most frequently carry
C protein antigens, while serotype III GBS rarely do. The GBS C protein antigens,
designated α and β, can elicit a protective response in mice immunized with either of the
antigens and challenged with C protein-carrying GBS (Michel et al, 1991; Madoff et al,
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1992). However, deletion of the typical 9 repeats of 82 amino acids in the α-C protein
alters the protein’s immunogenicity rendering it unrecognizable by antibody (Madoff et
al, 1996; Gravekamp et al, 1998). This type of antigenic variation is also seen with the
Rib protein, a α-C protein-like surface molecule found primarily on serotype III GBS
(Stalhammar-Carlemalm et al, 1993; Wastfelt et al, 1996).
The β-C component is a unique protein that functions as an IgA receptor by
binding the Fc portion of the antibody. The 130-kilodalton β-C protein has a long Nterminal signal sequence and a region in the C-terminus where every third residue is a
proline (Jerlstrom et al, 1991; Heden et al, 1991). Jerlstrom et al (1996) identified a 73
amino acid region in the C-terminal portion of the β-C protein that is responsible for IgA
binding.

By binding IgA via the Fc portion of the antibody, GBS interferes with

opsonophagocytosis and effective clearance.
Superoxide dismutase
In 1997 Gaillot and colleagues cloned the gene for a manganese-superoxide
dismutase (sodA) from GBS.

Initial experimental evidence suggested that sodA

functioned in protection against superoxide radicals generated as part of normal GBS
metabolic activities (Gaillot et al, 1997). sodA mutants created by allelic exchange are
more susceptible to oxidative stress and macrophage killing as well as show decreased
survival in the bloodstream and brains of mice following intraperitoneal injection (Poyart
et al, 2001). These results support a role for sodA in the protection of GBS against host
defenses.
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Purpose and Specific Aims
The purpose of this study was to examine the interactions between various
components of the human innate immune system and group B streptococcus and
determine what role these interactions might have on the GBS colonization process. In
general, immunity to GBS has been relatively underexplored and the mechanisms
contributing to colonization are unknown. We hypothesized that interactions between
GBS and the innate immune system may either contribute to the colonization process or
fail to prevent it. The following aims were used to test this hypothesis.
Aim 1:

To compare the phagocytic engulfment capacities of monocytes and

granulocytes from pregnant and nonpregnant, GBS-colonized and noncolonized women
in response to GBS. We examined the abilities of phagocytes from these groups of
women to engulf FITC-labeled GBS after 20 and 45 minutes of incubation. The mean
fluorescence intensity, which indicated the relative numbers of GBS engulfed, was
measured by flow cytometry.
Aim 2: To determine the potential killing capacities of monocytes and granulocytes from
pregnant and nonpregnant, GBS-colonized and noncolonized women in response to GBS.
Intracellular superoxide production subsequent to GBS engulfment was determined in a
flow cytometry based assay by measuring the increase in fluorescence following
oxidation of a nonfluorescent dye to a fluorescent one in the presence of superoxide.
Release of superoxide into the extracellular environment after GBS engulfment was
measured in a colorimetric assay.
Aim 3: To determine the mannose binding lectin exon-1 and promoter allele types and
serum concentrations in GBS-colonized and noncolonized women. Mannose binding
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lectin exon-1 alleles were determined by restriction fragment length polymorphim
analysis of PCR products of a 119bp region of the first exon of the gene. Mannose
binding lectin promoter alleles at two polymorphic sites was determined by sequence
specific oligonucleotide hybridization.

Mannose binding lectin protein levels were

measured by enzyme linked immunosorbant assay.
Aim 4: To determine the effects of cytokine exposure on GBS growth. GBS growth was
measured by optical density at 600 nm every hour for an 8-hour period during which
GBS was incubated with cytokine at concentrations of 0-100 ng/ml. Additional studies
examined potential synergism effects on GBS growth between interleukin-1β and
interleukin-6, as well as the requirement of interleukin-6 biologic activity for its growth
promoting effects.
Aim 5:

To determine whether or not GBS may bind interleukin-6.

The binding

interaction between GBS and FITC-interleukin-6 was measured by flow cytometry. The
interleukin-6 – GBS interaction was verified by pre-incubating the interleukin-6 with an
anti-human interleukin-6 blocking monoclonal antibody prior to addition to the GBS.
Aim 6: To determine the effects of IL-6 exposure on GBS virulence factors. RT-PCR
analysis was performed on cDNAs made from GBS incubated with and without
interleukin-6 using primers specific for a caspsular polysaccharide gene, a
cytolysin/hemolysin gene, and the C5a peptidase gene. Real time PCR was performed to
verify RT-PCR results.
Aim 7: To determine the effects of IL-6 exposure on global GBS gene expression.
Random arbitrarily primed PCR was performed on GBS incubated with and without
interleukin-6 exposure to identify genes with increased expression after interleukin-6
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exposure. The enhanced expression of genes identified by random arbitrarily primed
PCR was verified by real time PCR.
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This chapter addresses specific aims 1 and 2 by comparing the phagocytic

engulfment of GBS and the subsequent production of superoxide by phagocytes from
GBS-colonized and noncolonized women. These studies were designed to determine
whether or not interactions between the innate immune system and GBS differ in these
groups of women. Such differences in immune responses might lead to the undermining
of GBS clearance mechanisms and therefore contribute to the initiation of the
colonization process.
ABSTRACT
Objective: To evaluate the functional capacity of granulocytes and monocytes from
pregnant and nonpregnant women in relation to group B streptococcus (GBS)
colonization status.
Methods: Engulfment of fluorescent GBS by peripheral blood phagocytes from GBScolonized and noncolonized women was measured by flow cytometry. Intracellular
superoxide generated in response to GBS challenge to monocytes and granulocytes
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enriched from peripheral blood of these women was also measured by flow cytometry
and extracellular superoxide was determined by colorimetric assay.
Results: Monocytes and granulocytes from pregnant, GBS-colonized women engulfed
significantly greater numbers of GBS than phagocytes from pregnant, noncolonized
women or nonpregnant women regardless of colonization status.

No difference in

intracellular superoxide production was detected between any of the groups of women,
however monocytes from pregnant, colonized women released significantly more
superoxide into the extracellular milieu than did granulocytes from the same women. No
differences in extracellular release of superoxide were observed among noncolonized
women whether they were pregnant or not.
Conclusions: Monocytes from pregnant, colonized women engulf more GBS and release
more of the superoxide into the extracellular environment where it is unlikely to be an
effective defense mechanism against intracellular bacteria.

This suggests that

components of the innate immune system that should serve in a protective role may
function suboptimally thereby contributing to the colonization process by GBS.
KEY WORDS
phagocytosis; superoxide; flow cytometry
INTRODUCTION
Over the past thirty years group B streptococcus (GBS) has gained prominence as
the primary etiologic agent of sepsis, bacteremia, and meningitis in the neonatal period.
Administration of intrapartum antibiotics to women identified at risk for transmitting
GBS can be effective in prevention of transmission and early-onset disease1, but it fails to
address the underlying problem of maternal colonization. Despite estimates that between
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15 and 35% of women are asymptomatically colonized with GBS2 little is known as to
why GBS can evade the normal immune response in some women (colonized) and not in
others (noncolonized).
Phagocytic cells, particularly monocytes and granulocytes, are key mediators of
innate immunity to microorganisms, providing an early, rapid response to a potential
pathogen while the subsequent antigen-specific response is being initiated. Phagocytosis
of an organism stimulates production of microbicidal reactive oxygen species, including
superoxide radicals and hydrogen peroxide. Microbial degradation products generated
from the combined effects of the respiratory burst and cytolytic enzymes are then
processed and presented to induce either a T cell- or antibody-mediated response.
Alterations of these early steps in defense can lead to ineffective clearance of the
microorganism. While extreme examples of these defects such as leukocyte adhesion
deficiencies,3 or respiratory burst defects (chronic granulomatous disease)4 result in
severe, chronic bacterial and fungal infections, more subtle changes due to the unique
physiologic adaptations of pregnancy may be involved in the infectious conditions that
are particular threats to mothers and their newborns.
To evaluate the role that alterations in early innate immune responses to GBS may
play in supporting the colonization process, the phagocytic and respiratory burst
capacities of GBS-colonized and noncolonized women were compared. Because GBS
colonization is primarily an obstetric concern and the hormonal changes of pregnancy
influence immunologic functioning, comparisons were also made between pregnant and
nonpregnant women irrespective of colonization status.
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In this study we show that while pregnant women display an increased
engulfment of GBS, superoxide release from the phagocytic cells may be increased,
providing a possible explanation for colonization and modified adaptive immune
response in pregnancy.
SUBJECTS AND METHODS
Study Population
The populations studied consisted of pregnant and nonpregnant women recruited
from Marshall University School of Medicine and its associated obstetric clinics. All
patients were at least 18 years of age, had no other known active infections or immunodeficiency, and were not taking antibiotics in the previous six weeks. The study was
approved by the Marshall University School of Medicine Institutional Review Board and
each woman gave informed consent prior to participation. Peripheral blood from each
participant was drawn from the antecubital vein into EDTA Vacutainer tubes. Amies
clear StarSwabs were used to collect specimens for determination of GBS colonization
status. Swabs of the lower third of the vagina from pregnant patients were sent to the
Cabell Huntington Hospital laboratory as part of routine obstetric screening.

Self-

collected swabs from the nonpregnant patients were taken to the research laboratory. All
swabs were incubated in Lim broth for twelve hours at 37°C in 5%CO2. Aliquots of the
Lim broth culture were streaked onto tryptic soy agar with 5% sheep blood and incubated
overnight at 37°C in 5% CO2. Presumptive identification of GBS was based on colony
morphology, hippurate catalysis, and CAMP test (research laboratory only). Colonies
were confirmed as group B streptococcus by latex agglutination (Meritec Strep Group B
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Beta-hemolytic Streptococcus grouping set; Meridian Diagnostics, Inc., Cincinnati, OH)
by both laboratories.
Based on pregnancy status and the results from the vaginal swab cultures the
women were placed into four groups: pregnant, GBS-colonized (n = 9 for phagocytic
assays; n = 5 for superoxide assays), pregnant, noncolonized (n = 8 for phagocytic
assays; n = 5 for superoxide assays), nonpregnant, GBS-colonized (n = 3 for all assays),
and nonpregnant, noncolonized (n = 3 for all assays). For the pregnant, GBS-colonized
women the mean age was 26.5 years, gravidity ranged from 1 to 7, and parity ranged
from 0 to 4. For the pregnant, noncolonized women the mean age was 23.1 years,
gravidity ranged from 1 to 6, and parity ranged from 0 to 2. For the nonpregnant, GBScolonized women the mean age was 38.7 years and gravidity and parity were both 0. For
the nonpregnant, noncolonized women the mean age was 30.3 years and gravidity and
parity were both 0. All women were Caucasian with the exception of one pregnant,
noncolonized woman who was of American Indian heritage. All women were healthy
volunteers with medical insurance and with an estimated annual family income of greater
than $15,000.
Bacterial Preparation
Group B streptococci isolated from asymptomatic, colonized women during
routine gynecologic exams were assigned the designations 2118 and 2407 corresponding
to randomly assigned patient identification numbers.

GBS 2118 and 2407 were

serotyped as type V and type III, respectively, using a hemolytic streptococcus group B
typing sera kit (Accurate Chemical & Scientific Corp., Westbury, NY). GBS 2118 was
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used for the phagocytic engulfment assays due to poor fluorescence labeling of the type
III isolates like GBS 2407 used in the superoxide assays.
For the phagocytic engulfment assays GBS 2118 was labeled by incubation with
fluorescein isothiocyanate (FITC) 1 hydrochloride (Research Organincs, Cleveland, OH)
at 50µg/ml in Todd-Hewitt broth for 16 hours at 37°C in 5% CO2. The cultures were
centrifuged, washed twice with phosphate-buffered saline (PBS), and heat-killed at 60°C
for 45 minutes prior to resuspension to a final concentration of 108 bacteria/ml. After
confirming staining via flow cytometry (FACScan, Becton Dickinson, San Jose, CA) the
FITC-GBS were aliquoted and stored at -70°C until needed.
For the superoxide assays GBS 2407 was inoculated from frozen stocks and
cultured in Todd-Hewitt broth at 37°C in 5% CO2 until an optical density at 600nm
(OD600) of 0.4 was reached (approximately 4 hours).
Phagocytic Engulfment
Plasma was removed from 100µl of whole blood. The cell pellets were washed
twice in Dulbecco’s phosphate-buffered saline (DPBS) and resuspended in 100µl heatinactivated pooled human type AB serum (Sigma, St. Louis, MO). The pooled human
type AB serum failed to agglutinate GBS 2118 in a slide agglutination test. FITC-GBS
2118 was sonicated briefly to create a single-cell suspension prior to adding 10µl to each
tube of resuspended leukocytes. After incubation at 37°C on a rotary shaker for the
appropriate length of time, cytochalasin D (Sigma, St. Louis, MO) was added to each
tube (5µM final concentration). The contents of each tube were diluted with ice-cold
DPBS, centrifuged, and washed twice with cold DPBS. Erythrocytes were lysed using
ImmunoLyse (Coulter, Miami, FL) according to the manufacturer’s instructions. The
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leukocyte pellet was washed twice with DPBS and the cells were stained for
CD14(phycoerythrin-labelled clone TUK1; Caltag Laboratories, Burlingame, CA) to
allow for differentiation of leukocyte populations using flow cytometry. Stained cells
were fixed in 4% paraformaldehyde and analyzed by flow cytometry. Side light scatter
properties and CD14 staining were used to discriminate between monocytes and
granulocytes.

A minimum of 5000 events were collected for each population and

analyzed for the percentage of cells having engulfed FITC-GBS and for mean
fluorescence intensity using CellQuest Software (Becton Dickinson).
Superoxide Assays
Enriched populations of monocytes and granulocytes were used for measurements
of superoxide generated subsequent to engulfment of GBS 2407.

Monocytes were

enriched from whole peripheral blood by density gradient centrifugation using Ficoll
Paque Plus (Amersham Pharmacia Biotech, Piscataway, NJ) followed by negative
selection using the StemSep human monocyte enrichment system (Stem Cell
Technologies, Vancouver, British Columbia, Canada). Granulocytes were enriched from
the erythrocyte-granulocyte pellet from the density gradient centrifugation by dextran
sedimentation (500,000 average molecular weight; Sigma) followed by hypotonic saline
erythrocyte lysis. Viability was assessed by trypan blue staining and a minimum viability
of 90% was required for use in any assay. Purity of the enriched monocyte populations
was demonstrated using flow cytometry. Pure monocytes were positive for CD14 and
negative for CD3 (clone UCHT1; BD PharMingen, San Diego, CA) and CD19 (clone
HIB19; BD PharMingen).

Purity of the enriched granulocyte populations was

demonstrated using forward and side light scatter properties via flow cytometry.
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One hundred microliter aliquots of enriched monocytes or granulocytes (1 x 106
cells/ml) in PBS-gel were loaded with hydroethidine (10µM final concentration;
Polysciences Inc., Warrington, PA) for 15 minutes at 37°C. The cells were stimulated by
the addition of either phorbol 12-myristate 13-acetate (PMA) at a 200ng/ml final
concentration or 10µl of log-phase GBS 2407. The fluorescence level was immediately
determined by flow cytometry and was used as the zero time point. The granulocytes and
monocytes were incubated for 20 minutes and 45 minutes, respectively, at 37°C with the
stimulators before the final fluorescence reading was taken. A minimum of 5000 events
were collected for each population and analyzed for the percentage of cells with an
increase in fluorescence over time after stimulation.
In order to measure superoxide released from the monocytes and granulocytes
100µl aliquots of cells (1 x 106/ml) in PBS-gel were incubated for 45 minutes at 37°C in
5% CO2 with 25µl cytochrome c (2.7mg/ml; from horse heart), in the presence (25µl) or
absence of superoxide dismutase (1mg/ml; SOD; from bovine erythrocytes), and with
either 200ng/ml PMA or 10µl of log phase GBS 2407. Monocyte- and granulocyte-free
tubes were prepared as controls. After incubation the tubes were centrifuged and the
supernatants were transferred to a 96-well plate. The absorbance at 550nm was read and
used to calculate the nanomoles of superoxide released according to the following
formula: (experimental – matched cell-free control) – (experimental with SOD – matched
cell-free control) ÷ 47.4.
Statistical Analysis
Statistical analyses were performed using the SigmaStat software package (Jandel
Scientific Software, San Rafael, CA). The Student’s t-test was used for comparisons of
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pregnant versus nonpregnant women and colonized versus noncolonized women. P <
0.05 was considered statistically significant. The t-test sample size program (alpha =
0.05 and power = 0.8) was used to estimate the number of individuals needed to provide
statistical significance when P > 0.05.
RESULTS
Phagocytic Engulfment
The percentages of monocytes and granulocytes having engulfed FITC-GBS 2118
were measured by flow cytometry and compared between GBS-colonized and
noncolonized women. No significant differences were observed between these groups of
women regardless of pregnancy status (TABLE 1).
Although no differences in the percentages of phagocytes having engulfed FITCGBS 2118 were observed, measurements of mean fluorescence intensity revealed a
significant difference in the relative number of FITC-GBS 2118 taken up by phagocytes
from pregnant, colonized women when compared to pregnant, noncolonized women.
Granulocytes from pregnant, colonized women engulfed approximately twice the number
of FITC-GBS 2118 after 20 and 45 minutes that those from pregnant, noncolonized
women (Fig. 1A). Monocytes from pregnant, colonized women engulfed greater than
five times the number of FITC-GBS 2118 after 45 minutes than those from pregnant,
noncolonized women (Fig. 1A). These differences were not observed for nonpregnant
women (Fig. 1B) or in parallel experiments substituting Staphylococcus aureus (ATCC
25923) for GBS 2118 (data not shown).
Superoxide Assays
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TABLE 1. Percentagesa of phagocytes having engulfed FITC-GBS 2118 over time
Pregnancy
Status

Colonization
Status
Colonized
(n = 9)

Cell
Type

% Phagocytes Containing GBS
20 min.
45 min.

Monocytes

55.9 ± 7.8

69.1 ± 12.8

Granulocytes

58.6 ± 18.6

79.1 ± 14.3

Monocytes

34.7 ± 7.8

42.0 ± 19.2

Granulocytes

29.4 ± 11.4

40.7 ± 18.7

Monocytes

48.4 ± 14.9

55.5 ± 14.1

Granulocytes

52.3 ± 21.2

67.3 ± 19.4

Monocytes

37.4 ± 15.5

44.1 ± 11.6

Granulocytes

25.6 ± 9.8

37.1 ± 30.0

Pregnant
Noncolonized
(n = 8)

Colonized
(n = 3)
Nonpregnant
Noncolonized
(n = 3)
a

Means ± standard deviation.
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Fig. 1. Mean fluorescence intensity of engulfed FITC-GBS 2118 over time. Monocytes
and granulocytes from colonized (black bars) and noncolonized (white bars), pregnant
(A) and nonpregnant (B) women were incubated with FITC-GBS 2118 for 45 min. Mean
fluorescence intensity was measured using flow cytometry.

Significant differences

between colonized and noncolonized women are denoted by asterisks (p<0.05 using
Student’s t-test). Pregnant, colonized: n = 9; pregnant, noncolonized: n = 8; nonpregnant,
colonized: n = 3; nonpregnant, noncolonized: n = 3.
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Preliminary experiments were conducted to determine the time and PMA
concentration required for optimal superoxide production. The concentrations and time
superoxide (0.78±0.8 nmol) into the extracellular environment than did the granulocytes
points used in both superoxide assays reflected maximal PMA as well as GBS
stimulation.
A comparison of the percentages of enriched monocytes and granulocytes
producing intracellular superoxide in response to challenge with log-phase GBS 2407
failed to show significant differences between GBS-colonized and noncolonized women
regardless of pregnancy status (Fig. 2).
Not all superoxide generated intracellularly remains as such. Extracellular release
of superoxide by enriched monocytes and granulocytes in response to challenge with logphase GBS 2407 was measured spectrophotometrically after 45 minutes. No significant
differences between colonized and noncolonized women were detected.

However,

monocytes from pregnant, colonized women released a significantly greater amount of
from these same women (0.0±0.0 nmol) (Fig. 3A). This difference was not observed for
noncolonized women regardless of pregnancy status (Fig. 3A, B). Parallel experiments
with S. aureus 25923 again demonstrated the specificity of these differences in relation to
GBS (data not shown).
DISCUSSION
Despite recent efforts to devise more accurate and cost-effective methods for
identifying and treating pregnant women at risk of transmitting GBS to their newborns
much remains to be learned concerning basic immunity to GBS. Perhaps the most
important issue in this area is why certain women become colonized with GBS while
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Fig. 2. Generation of intracellular superoxide after stimulation with PMA or GBS 2407.
Enriched populations of monocytes and granulocytes from colonized (black bars) and
noncolonized (white bars), pregnant (A) and nonpregnant (B) women were loaded with
hydroethidine prior to incubation at 37°C with PMA (200ng/ml) or log-phase GBS 2407.
The increase in fluorescence due to superoxide oxidation of hydroethidine to ethidium
bromide was measured using flow cytometry at 20 minutes (granulocytes) and 45
minutes (monocytes) after stimulation. No significant differences among any of the
groups were observed.
noncolonized: n = 3.
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Pregnant, colonized and noncolonized: n = 5; nonpregnant,
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Fig. 3. Release of superoxide into the extracellular milieu following stimulation with
PMA or GBS 2407.

Enriched populations of monocytes and granulocytes from

colonized (black bars) and noncolonized (white bars), pregnant (A) and nonpregnant (B)
women were stimulated with PMA (200ng/ml) or log-phase GBS 2407 for 45 minutes at
37°C.

The nanomoles of superoxide released were calculated from changes in

absorbance at 550nm. Significant differences between monocytes and granulocytes from
pregnant, colonized women are denoted by asterisks (p<0.05 using Student’s t-test).
Pregnant, colonized and noncolonized: n = 5; nonpregnant, colonized and noncolonized:
n = 3.
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others effectively eliminate it. We have proposed that the way the innate immune
system in GBS-colonized women responds to GBS differs from that in noncolonized
women and that these differences may assist in the initiation of colonization. To test this
proposal we compared the abilities of phagocytes from colonized and noncolonized
women to engulf GBS and generate the microbicidal superoxide radical following
engulfment. Possible contributions due to pregnancy were also evaluated by comparing
responses from pregnant and nonpregnant women.
While no differences in the number of phagocytes having engulfed GBS were
observed for any of the groups of women, the bacterial load in phagocytes from pregnant,
colonized women was significantly greater than for pregnant, noncolonized women. This
effect was probably not due to opsonic antibody since heterologous serum that failed to
agglutinate GBS was used in these assays. Both granulocytes and monocytes from
pregnant, GBS-colonized women engulfed greater numbers of GBS. Although overall
enhanced phagocytic ability is frequently observed during pregnancy5,6,7 the greater than
five-fold increase in engulfment by monocytes and the two-fold increase in engulfment
by granulocytes from pregnant, GBS-colonized women appears to be specific to GBS as
these differences were not observed in parallel experiments with S. aureus.
Following phagocytic engulfment of GBS, superoxide is generated within the
phagocyte by phagosome-associated NADPH oxidase. Not surprisingly, differences with
regard to the percentage of phagocytes producing superoxide were not seen, but there was
a difference with respect to pregnant, GBS-colonized women in the amount of superoxide
released from monocytes versus granulocytes.

The release of superoxide into the

extracellular environment was greater from monocytes in pregnant, GBS-colonized
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women. Granulocytes from these women failed to release any superoxide extracellularly.
The mechanism underlying the release of superoxide generated within the
phagosome into the extracellular environment is unclear. Two possible explanations can
be envisioned, one phagocyte-associated and one GBS-associated. The respiratory burst
associated with phagocytic engulfment is activated following specific microbe-phagocyte
receptor interactions. If the respiratory burst is activated through these interactions prior
to complete closure of the phagosome, superoxide could leak into the extracellular
environment. Alternatively, factors produced by GBS may break down the phagocyte
membrane integrity leading to leakage of superoxide outside the cell. Studies have
shown that GBS can cross various types of eukaryotic cell membranes including those
from human chorion cells,8 human umbilical vein endothelial cells,9 human lung
epithelial cells,10 and human monocytes.11 Using GBS serotype III strains producing
different levels of β-hemolytic activity9,10 or using agents that inhibit GBS β-hemolysin11
it has been demonstrated that the β-hemolysin produced by GBS disrupts cellular
membranes, alters membrane permeability, and causes the release of lactate
dehydrogenase. Based on the findings of these studies it can be argued that the βhemolysin produced by GBS 2407, the serotype III isolate used in our superoxide assays,
may damage the plasma and/or phagosome membranes leading to a release of superoxide
into the extracellular environment. Both of these possible mechanisms for the release of
superoxide are subjects for future investigations, perhaps by using strains with a deletion
of the β-hemolysin gene.
Although a number of studies have investigated the interactions between GBS and
phagocytes, only one employs flow cytometry to measure phagocytic engulfment and
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superoxide production.12 In that study the authors report that phagocytosis of GBS and
superoxide production after ingestion are greater for neutrophils than for monocytes, but
does not evaluate the effect of pregnancy which may explain the differences with our
study. In addition to differences in study populations, McCloskey and Salo12 uses GBS
incubated with antibody and complement to examine opsonophagocytosis. In contrast
our study used unopsonized GBS to examine engulfment.
In that colonization status, as well as pregnancy, defined our study populations we
were aware that differences in sample collection techniques would inevitably lead to
variations in GBS recovery rates. We elected to allow the physician to determine the
collection procedure. As only lower vaginal segment GBS colonization was examined in
our study, GBS carriage may have been modestly underestimated. However, statistical
sample size evaluation suggested that the addition of more subjects was unlikely to alter
the conclusions of the study.
The results of our investigations indicated a unique interaction between GBS and
monocytes from pregnant, GBS-colonized women. GBS may accumulate in large
numbers in monocytes from colonized, pregnant women, which tend to release their
superoxide into the extracellular milieu. Superoxide is most likely to be more potent
when sequestered in an intracellular location therefore, these monocytes, which have
released their superoxide, may in effect create an intracellular niche for GBS. Other
recent studies support the idea that monocytes provide an intracellular haven for GBS.
Several groups have reported that GBS can persist intracellularly in murine macrophages
for 24 to 48 hours following infection13,14 as well as inactivate the protein kinase C
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pathway, one of the main signal transduction pathways leading to macrophage
activation.14
The alterations in innate immune response by monocytes from pregnant,
colonized women demonstrated here provide the initial evidence that the immune system,
which should function in a protective fashion, may not contribute to the prevention of
GBS colonization. These alterations are by no means the only contributory factors in the
colonization process, but provide a framework for further dissection of the underlying
mechanism. In the process of elucidating the mechanism leading to GBS colonization
more information on the immune response to GBS will be generated and may provide a
clearer path to the design of an effective GBS vaccine.
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CHAPTER 3. ELEVATED SERUM MANNOSE BINDING LECTION IN GROUP
B STREPTOCOCCUS COLONIZED WOMEN
A paper to be submitted to the Journal of Infectious Diseases.
Jennifer M. Smith1, Xuejun Peng2, Stephen K. Hunter3, and Susan H. Jackman1
1
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Results from the studies presented in the previous chapter demonstrated that there
is enhanced internalization of GBS by phagocytes from pregnant, GBS-colonized women
in comparison to noncolonized women. This increased engulfment may be mediated in
part by opsonization with GBS-specific antibody, complement, or lectins. We know
from the design of the previous experiments that antibody and complement were not
potential opsonins under those conditions. Therefore we chose to investigate the role one
of the lectins, mannose binding lectin, may play in phagocytosis of GBS.

These

experiments addressed specific aim 3.
ABSTRACT
Mannose binding lectin (MBL) gene polymorphisms and serum concentrations
were examined in GBS-colonized and noncolonized women.

PCR and restriction

fragment length polymorphism analysis was used to identify individuals with variant
alleles for exon-1 of the MBL gene. Sequence-specific oligonucleotide hybridization was
used to identify individuals with polymorphisms at two loci in the MBL gene promoter
region. Serum MBL concentrations were determined by ELISA. No associations were
observed between GBS colonization status and MBL gene polymorphisms. However,
ELISA data indicated that there was an increased serum level of MBL in GBS-colonized
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women compared to noncolonized women (P = 0.0114). In a flow cytometry-based
phagocytosis assay, increased serum MBL levels were associated with increased
engulfment (P < 0.05). This association between serum MBL levels, GBS colonization,
and increased phagocytosis suggests that MBL may be involved in enhanced engulfment,
which leads to the creation of an intracellular niche and persistent colonization.
INTRODUCTION
Group B streptococcus (GBS) has emerged as the most prevalent cause of
pneumonia, sepsis, and meningitis during the neonatal period. The majority of lifethreatening GBS infections are transmitted from a colonized mother to her infant during
the birthing process. As such, maternal colonization in the vagina and/or rectum is a
major risk factor for neonatal GBS disease. In the United States this puts 15-35% of the
female population in danger of passing GBS to the newborn [1]. In spite of such a large
group at risk, little is understood concerning the events contributing to persistent
colonization with GBS in some women.
The collectin family of serum proteins function as mediators in the nonspecific
immune response by binding surface carbohydrates of microorganisms. This collectinmicrobe interaction enhances phagocytosis and microbial clearance. In addition to acting
directly as an opsonin [2], mannose binding lectin (MBL) is capable of activating both
the classical [3] and alternative [4] complement cascades. The importance of the role
MBL plays in host immune responses is underscored by numerous studies examining the
relationships between MBL and infectious and inflammatory diseases. Deficiencies in
MBL due to polymorphisms in the promoter and mutations in exon-1 of this gene are
associated with susceptibility to infections by a variety of microorganisms, including N.
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meningitidis [5], P. falciparum [6], and C. neoformans [7].

However, with some

intracellular microbes, like L. chagasi [8], MBL deficiency may protect against infection
by blocking entry into host cells.
Because MBL functions to enhance microbial engulfment by host cells, we
examined the relationship between mannose binding lectin and GBS colonization. Our
data did not demonstrate a relationship between any of the MBL gene mutations and
polymorphisms associated with MBL serum protein deficiency and GBS colonization. In
fact, significantly higher levels of serum MBL protein were observed in women
colonized with GBS. Additionally, at high serum concentrations of MBL, engulfment of
GBS by phagocytes was significantly increased.
MATERIALS AND METHODS
Subjects. Sixty-eight reproductive age women were recruited from Marshall University
Joan C. Edwards School of Medicine, Huntington, WV, and an obstetric and gynecology
clinic at the University of Iowa, Iowa City, IA. Participants were grouped as GBScolonized or noncolonized according to results of cultures from ano-vaginal swabs.
Racial composition, socioeconomic status, age, gravidity, and parity were similar for both
groups.
DNA Isolation from Blood Spots. Blood from EDTA Vacutainer tubes or fingersticks
were spotted onto Whatman filter paper or FTA Cards (Life Technologies, Rockville,
MD). Blood spots on filter paper were fixed in methanol and air-dried while those on
FTA Cards were allowed to air dry over night. Two 2 mm disks were removed from the
dried blood spots. DNA was released from the filter paper disks by boiling for 10
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minutes in sterile, deionized water and from the FTA cards using FTA Extraction
Reagent (Life Technologies).
MBL Exon-1 and RFLP. DNA extracts were used as the template in PCR reactions and
subsequent RFLP analysis as previously described [9]. Briefly, a 119-bp region of the
first exon of the MBL gene was amplified by PCR and then digested by Ban I, Mbo II, or
Mlu I. Restriction digestion banding patterns were used to identify the alleles as either
wild-type or B, C, and D variants (See Appendix B, Figure 1).
MBL Promoter PCR and Sequence-specific Oligonucleotide (SSO) Hybridization. The
MBL gene promoter from –801 to +77 was amplified from DNA extracted from blood
spots in PCR reactions as described previously [10]. The PCR product was transferred to
a nylon membrane by slot blot. MBL promoter allele SSO probes labeled using the
BrightStar Psoralen-Biotin Nonisotopic Labeling Kit (Ambion, Austin, TX) were
hybridized to the slot blot in TMAC hybridization buffer (50 mM Tris, pH 8; 3 M
tetramethlyammonium chloride; 2 mM EDTA; 0.1% SDS; 5X Denhardt’s solution; 100
µg/ml herring sperm DNA) for 3 hours with gentle shaking at 54°C. The membranes
were then washed twice with 2X SSPE (3 M NaCl; 20 mM NaH2PO4; 2 mM EDTA, pH
7.4) at room temperature and twice with TMAC at 59°C. Probe hybridization was
detected using the BrightStar BioDetect Nonisotopic Detection Kit (Ambion).
MBL Serum ELISA. Serum was collected in Vacutainer tubes without anticoagulant and
frozen at -20°C until use. Nunc MaxiSorp microplates (Fisher Scientific, Pittsburgh, PA)
were coated with 1 µg/ml mouse anti-human mannan binding lectin monoclonal antibody
clone HYB131-01 (Statens Serum Institute, Copenhagen, Denmark) overnight at 4°C.
The plates were blocked with PBS-Tween 20 (PBS-T) for two hours at room temperature.
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Serum samples were diluted 1:10 in PBS-T and aliquoted into duplicate wells. MBL
standard and deficient sera (Statens Serum Institute) were diluted 1:10 and then serially
diluted at 1:2 in PBS-T. The plate was incubated overnight at 4°C. After washes with
PBS-T, 0.5 µg/ml biotinylated HYB131-01 (Statens Serum Institute) was added and the
plate was incubated for one hour at room temperature. Following washes with PBS-T,
horseradish peroxidase avidin D (Vector, Burlingame, CA) was added to each well and
incubated for 30 minutes at room temperature.

Following washes 2,2’-azino-bis(3-

ethylbenzthiazoline-6-sulfonic acid) (Vector) was added and color was allowed to
develop for 30 minutes after which the absorbance was measured at 504 nm. A standard
curve was created from MBL standard serum samples by linear regression using
SigmaStat 2.03 software (Jandel Scientific, San Rafael, CA). Serum MBL concentrations
of test samples were calculated using the regression equation and reported in ng/ml.
Phagocytic Engulfment. Phagocytic engulfment was measured as described previously
[11] with minor modification. The cell pellet from a small aliquot of whole blood was
resuspended in two-fold serial dilutions of MBL standard serum (in PBS with 5 mM
CaCl2) prior to incubation with FITC-GBS for 45 minutes at 37°C. After erythrocyte
lysis and fixation in 2% paraformaldehyde, flow cytometry was used to analyze the
percentage of phagocytes having engulfed FITC-GBS.
Statistics. The association between MBL gene polymorphisms and GBS colonization
was analyzed by either Chi-squared or Fisher’s Exact test according to the number of
observations in each category. Wilcoxon rank sum test or Kruskal-Wallis test was used
to analyze the difference in MBL serum concentrations between MBL gene
polymorphisms and GBS colonization. Percentages of phagocytes having engulfed GBS
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at different serum MBL concentrations were compared by one-way analysis of variance
with the Tukey test for multiple comparisons. P < 0.05 was considered statistically
significant.
RESULTS
Due to the innate immune functions attributed to mannose binding lectin and the
association between MBL deficiency and infectious disease, MBL exon-1 alleles were
examined by PCR and RFLP analysis in GBS-colonized and noncolonized women.
Exon-1 alleles were identified as wild type or B, C, and D variants according to the
restriction digestion banding pattern (See Appendix B, Figure 1).

Seventeen GBS-

colonized and thirty noncolonized women carried the wild-type alleles (table 1). Of the
12 GBS-colonized women with variant exon-1 alleles, 10 were heterozygous for the B
allele and 2 were heterozygous for the D allele. Of the 9 noncolonized women with
variant alleles, 5 were heterozygous for the B allele, 3 were heterozygous for the D allele,
and 1 was heterozygous with both the B and D alleles. In both groups of women B and D
allele homozygotes and C variant alleles were not observed. A relationship between
MBL exon-1 alleles and GBS colonization was not detected (χ2 = 0.1062).
Since GBS colonization was not associated with variant exon-1 alleles,
polymorphisms at two sites within the MBL gene promoter were analyzed using SSO
hybridization in 26 of the GBS-colonized women and 24 of the noncolonized women.
Alleles were identified as either L or H at the –550 polymorphic site and as either X or Y
at the –221 polymorphic site in the MBL promoter region. Association between these
polymorphisms at the –550 or –221 promoter sites and GBS colonization was also not
detected (table 1).
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Table 1. Relationship between MBL alleles and GBS colonization.
Exon-1 Allele Type
Colonization
Status

Wild-type

Promoter Allele Type

Varianta

-550 siteb

-221 sitec

LH

LL

HH

XX

XY

YY

GBS +

17

12

15

11

0

1

23

2

GBS -

30

9

12

12

0

4

20

0

a

Variant refers to the number of individuals heterozygous for any variant allele.

b

The –550 polymorphic site in the MBL promoter has alleles designated L and H. The

values below represent the number of women with the specified allele combination at that
site.
c

The –221 polymorphic site in the MBL promoter has alleles designated X and Y. The

values below represent the number of women with the specified allele combination at that
site.
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In addition to examining a potential relationship between MBL and GBS
colonization at the genetic level, serum MBL protein concentrations were measured by
ELISA. When all subjects were considered together, an association between women with
the wild-type exon-1 alleles and higher levels of MBL was observed (P = 0.048; See
Appendix B, Figure 2) which is similar to reports from others [9]. Interestingly, when
comparing GBS-colonized versus noncolonized women, serum MBL protein quantities
were significantly elevated in GBS-colonized women (P = 0.0114) as illustrated in figure
1A.
In order to evaluate the role MBL may play in phagocytic engulfment of GBS, a
flow cytometry-based assay using serum with a known MBL concentration as a source of
opsonin and peripheral blood phagocytes from normal, healthy volunteers was
performed.

Engulfment of GBS by phagocytes in the presence of MBL serum

concentrations ranging from 3340 ng/ml to 104 ng/ml was measured. Figure 1B shows
that at high concentrations of MBL internalization of GBS is significantly increased (P <
0.05), while lower concentrations (<1670 ng/ml) did not appear to enhance phagocytosis.
DISCUSSION
Studies linking deficiencies in serum mannose binding lectin protein with
susceptibility to a multitude of infections emphasize the role of MBL as a mediator of
innate immunity. Because of its demonstrated importance in host defense, we examined
the possibility that a deficiency in MBL was associated with GBS colonization. Our
initial data examining the frequencies of the MBL gene alleles associated with MBL
deficiency indicated a strong association between variant exon-1 alleles and GBS
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Figure 1. Associations between serum MBL concentration, GBS colonization status, and
phagocytic engulfment.

A. Increased serum MBL concentration in GBS-colonized

women (n = 19) compared to noncolonized women (n = 11). P = 0.0114. B. Phagocytic
engulfment of GBS is dependent on serum MBL concentration. Asterisk indicates P <
0.05 when comparing to MBL concentration of ≥ 1670 ng/ml to concentrations ≤ 1670
ng/ml.
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colonization [12]. However, with the inclusion of more subjects, the significance of this
relationship was reduced and, additionally, no correlation between the MBL promoter
polymorphisms and colonization was observed (table 1). Finding no genetic association
between MBL and GBS colonization status, we expected that MBL serum concentrations
would be similar in both GBS-colonized and noncolonized women. However, the data
revealed that GBS-colonized women had significantly higher levels of serum MBL than
did noncolonized women (figure 1A). From these findings the question arose as to
whether MBL assists in establishing persistent GBS colonization in some women. Using
a phagocytic engulfment assay, we found that enhanced uptake of GBS was observed at
increased serum levels of MBL.
The data presented here demonstrate that both enhanced GBS engulfment and
GBS colonization status were associated with increased serum MBL levels.

This

supports our previous study showing that phagocytes from pregnant, colonized women
engulf significantly greater numbers of GBS than pregnant, noncolonized women [11].
These data suggest that MBL may act to augment the creation of a protective niche for
GBS within the phagocyte since others [13, 14] have indicated that upon engulfment by
murine macrophages GBS survive intracellularly for 24-48 hours.
Similar to our findings, De Miranda Santos et al [8] report that there is a strong
association between MBL serum concentrations and susceptibility to visceral
leishmaniasis. High levels of serum MBL (2888 ng/ml) were observed in patients with a
history of visceral leishmaniasis and low levels (944 ng/ml) were observed in individuals
with negative leishmanin skin tests [8].

Perhaps most interestingly, asymptomatic

individuals with a positive leishmanin skin test had intermediate serum MBL
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concentrations (1113 ng/ml) [8], which are similar to the levels recorded for our
asymptomatic GBS-colonized women (1344 ng/ml).
Our results suggest that MBL may function to enhance engulfment of GBS in
colonized women, which at first glance would appear to conflict with previous data by
Butko et al [15] suggesting that MBL is not an opsonin for serotype III GBS. Two
important differences exist between our research design and that of Butko et al: 1) in
Butko et al, the study population is composed of volunteers whose GBS colonization
status is not known whereas ours is a comparison of GBS-colonized and noncolonized
women and 2) their measure of phagocytosis is bactericidal index while ours was GBS
engulfment.

Therefore, the discrepancies in our work and Butko et al are easily

explained by differences in study populations and experimental design.
The findings presented in this study and our previous work indicate that MBL
may mediate phagocytic engulfment of GBS in colonized women and that this pathway
could provide entry into an intracellular niche allowing GBS to evade clearance and
establish persistent colonization.
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Figure 1. Mannose binding lectin exon-1 RFLP patterns. A 119bp segment of exon-1 of
the MBL gene was amplified by PCR and digested by MboII, BanI, or MluI restriction
endonucleases. Allele type was determined by RFLP pattern. (Top) The wild-type allele
was indicated by an uncut 119bp band in the MboII and MluI lanes and an 84bp band in
the BanI lane. This panel is representative of an individual homozygous for the wild-type
allele.

(Middle) The B allele was indicated by elimination of the BanI restriction

endonuclease site and the presence of the 119bp band in the BanI lane. This panel is
representative of an individual heterozygous for the B allele. (Bottom) The D allele was
indicated by the insertion of an MluI restriction endonuclease site and the presence of a
95bp band in the MluI lane. This panel is representative of an individual heterozygous
for the D allele. The C allele would have been indicated by the insertion of an MboII
restriction endonuclease site and would have demonstrated a 79bp band in the MboII
lane, however a C allele was not detected in any of the women in this study.
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Figure 2. MBL exon-1 allele type and serum MBL concentration. MBL concentration
was significantly higher in individuals with the wild-type alleles (n = 21) than in
individuals that were heterozygous for a variant allele (n = 9) by Wilcoxon Rank Sum
test (P = 0.048).
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CHAPTER 4. ENHANCEMENT OF GROUP B STREPTOCOCCUS GROWTH
AND VIRULENCE BY INTERLEUKIN-6
A paper to be submitted to Infection and Immunity.
Jennifer M. Smith1,2 and Susan H. Jackman1,2
1

Department of Microbiology, Immunology, & Molecular Genetics
2
Department of Obstetrics & Gynecology
Marshall University Joan C. Edwards School of Medicine, Huntington, WV
This chapter addresses interactions between another component of the innate
immune system, pro-inflammatory cytokines, and GBS. Multiple reports indicate that
cytokines may have a profound effect on bacterial growth and virulence. Therefore, we
examined the effects of three pro-inflammatory cytokines on GBS growth and virulence.
These experiments addressed specific aims 4-7.
ABSTRACT
Sepsis due to group B streptococcus (GBS) is mediated by the overwhelming
release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Incubation of
GBS with these cytokines revealed that IL-1β and IL-6 concentrations of 100 ng/ml
significantly enhanced GBS growth. However only for IL-6 is this level within the
physiologic range observed during sepsis.

Specific binding of IL-6 to GBS was

demonstrated in a flow cytometry-based assay using FITC-conjugated IL-6. In addition
to evaluate the effects of IL-6 on growth, mRNA expression of three common virulence
factors was examined by RT-PCR and real time PCR. Only expression of the C5a
peptidase was increased in response to IL-6 exposure. RAP-PCR was then used to
globally identify additional GBS genes upregulated in response to IL-6. One of four
products with increased expression after IL-6 exposure, an ATP-binding protein
(ATPase) of an ABC transporter, appeared to be part of the operon encoding the GroES
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and GroEL proteins which have been implicated in the pathogenesis of other bacterial
species. Real time PCR verified the upregulation of mRNA expression of the ATPase as
well as that of the GroE genes. Identification of other genes altered in response to IL-6
will provide a better understanding of GBS pathogenesis as well as reveal potential
targets for future therapeutics.
INTRODUCTION
Group B streptococcus (GBS) is the primary etiologic agent associated with lifethreatening bacterial infections in the neonatal period. In the hours or days following
birth, infants infected by vertical transmission from a mother ano-vaginally colonized
with GBS present with pneumonia, meningitis, or sepsis. Neonates with GBS sepsis have
elevated plasma levels of pro-inflammatory cytokines, including tumor necrosis factor-α
(TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (6). Such increases in cytokine
concentrations, particularly TNF-α and IL-6, are associated with high mortality rates in
both infants (37) and adults (36) with sepsis.
The cytokine network supplies important cues to surrounding tissues that lead to a
myriad of host cellular responses. Characterization of bacterial responses to the host’s
cytokine milieu is a newly emerging field. Recently, cytokines including interleukin-2,
granulocyte-macrophage colony-stimulating factor, and interleukin-1 have been observed
to enhance E. coli growth (7, 30), while IL-6 can stimulate growth of P. aeruginosa (26)
and M. avium (8).
The effects that the sepsis-associated cytokine-enriched environment may have on
GBS have yet to be explored. We hypothesized that the pro-inflammatory cytokines
induced by GBS infection may enhance the bacteria’s growth and virulence
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characteristics. We found that IL-6 enhanced GBS growth at high, but physiologically
relevant, concentrations; that IL-6 specifically binds GBS; and that IL-6 increases
expression of virulence-associated genes.
MATERIALS AND METHODS
Bacteria.

A serotype III GBS strain, designated 2407, was isolated from an

asymptomatic, colonized woman during a routine gynecologic exam. GBS 2407 was
inoculated into Todd Hewitt broth (THB) and incubated overnight in 5% CO2 at 37°C.
Equal volumes of overnight culture and sterile 24% glycerol in phosphate buffered saline
(PBS) were stored at -70°C until needed.
Cell culture. The human hepatoma cell line HuH-7, generously provided by Dr. Stanley
M. Lemon from The University of Texas Medical Branch at Galveston, was maintained
in RPMI-1640 (Life Technologies, Rockville, MD) supplemented with 10% heatinactivated fetal bovine serum (Life Technologies) and 25 µg/ml M-Plasmocin
(InvivoGen, San Diego, CA) at 37°C in 5% CO2.
Incubation of GBS 2407 with cytokines. THB inoculated with GBS 2407 from frozen
stock was incubated overnight in 5% CO2 at 37°C. The cultures were centrifuged at 1400
× g for 10 minutes and washed twice with RPMI-1640 without phenol red (Life
Technologies).

Approximately 106 CFU/ml GBS 2407 were added to RPMI-1640

without phenol red containing varying concentrations (0, 1, 10, 100 ng/ml) of
recombinant human TNF-α, IL-1β, or IL-6 (R & D Systems, Minneapolis, MN) and
incubated in 5% CO2 at 37°C for 8 hours. GBS 2407 growth was measured by optical
density at 600 nm each hour. All growth experiments were repeated three times.
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Co-incubation of GBS 2407 with IL-1β and IL-6 was performed as above with
the exception that one cytokine concentration was held at 10 ng/ml while the other was
varied (0, 1, 10, 100 ng/ml).
Binding of IL-6 to GBS 2407. Binding of GBS 2407 was detected by flow cytometry
using the human interleukin 6 biotin conjugate Fluorokine kit (R & D Systems).
Approximately 106 CFU/ml GBS 2407 were incubated with human IgG (Sigma, St.
Louis, MO) at 1mg/ml/106 cells for 15 minutes in order to block potential Fc-mediated
interactions. Biotinylated IL-6 was added to the blocked cells and incubated for 1 hour at
4°C. Following this incubation, avidin-FITC was added and the cells were incubated for
30 minutes at 4°C in the dark. After washing, the cells were suspended in RDF1 buffer
included in the Fluorokine kit. IL-6 binding to GBS 2407 was detected using a FACScan
flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) with
CellQuest software and measured by an increase in fluorescence greater than that of GBS
2407 incubated with the negative control protein, biotinylated soybean trypsin inhibitor.
Pre-treatment of the biotinylated IL-6 with an anti-human IL-6 blocking antibody prior to
addition to the Fc-blocked GBS 2407 cells demonstrated that the interaction with GBS
was specific for IL-6.
RNA isolation and cDNA synthesis.

GBS 2407 total RNA was isolated using

modifications of the Trizol (Life Technologies) protocol or the RNeasy Mini Kit (Qiagen,
Valencia, CA). Bacteria were pelleted at 1400 × g for 10 minutes, washed with DEPCtreated water (Ambion, Austin, TX), and snap-frozen in liquid nitrogen. The frozen GBS
2407 pellets were lysed in either Trizol reagent or RNeasy buffer RLT using the MiniBeadBeater (BioSpec Products, Bartlesville, OK) and 0.1 mm zirconia-silica beads
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(BioSpec Products) for 3 minutes at 5000 rpm. After the beads settled, the lysate was
removed and RNA was extracted according to the manufacturer’s instructions. All RNA
samples were stored in DEPC-treated water at -70°C.
RNA was obtained from HuH-7 cell monolayers by lysing in the culture dish
using Trizol reagent.

Total RNA was isolated according to the manufacturer’s

instructions and stored in DEPC-treated water at -70°C.
One microgram of total RNA from either GBS 2407 or HuH-7 cells was reverse
transcribed to cDNA in a standard reaction using Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (Life Technologies) and random hexamer primers. Parallel
samples were run without the addition of M-MLV reverse transcriptase to be used as a
negative control in the PCR reactions.
PCR. Standard 50 µl PCR reactions using 1 µl cDNA, 0.4 µM GBS gene-specific
primers and 2.5 U AmpliTaq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) were
conducted under the following conditions: 30 cycles of 95°C for 45 seconds, 53°C for 45
seconds, and 72°C for 1 minute, with a final 7 minute extension at 72°C. Sequences of
GBS gene-specific primers designed using OLIGO 5.0 (National Biosciences, Hamel,
MN) and synthesized by the Marshall University DNA Core Facility are listed in Table 1.
PCR products were visualized on a 3% NuSieve-GTG and SeaKem-GTG agarose
(BioWhittaker Molecular Applications, Rockland, ME) gel containing GelStar nucleic
acid stain (BioWhittaker Molecular Applications). Gels were photographed with the
Kodak Digital Science 1D Electrophoresis Documentation and Analysis System and band
intensities were measured with the system’s associated software (Eastman Kodak
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Table 1. GBS-specific primer sequences.
Primer name

Sequence

Source (Ref.)

16S forward

5'GCGGCTCTCTGGTCTGTAAC3'

Genbank Z22808 (32)

16S reverse

5'TAAGGTTCTTCGCGTTGCTT3'

Genbank Z22808 (32)

cpsE forward

5'GCAGAAGCGACGCCTTAGTT3'

Genbank AF163833 (3)

cpsE reverse

5'GCTCCTGTCCCGAGTAAAAC3'

Genbank AF163833 (3)

scpB forward

5'GCCAATAGCAGCAAACAAGT3'

Genbank U56908 (5)

scpB reverse

5'GCCAAAATCACCTCGGAAAC3'

Genbank U56908 (5)

cyl forward

5'ATAGCCTTTCTTTTCCACTG3'

Genbank AF157015(31)

cyl reverse

5'TGCCATAATCCTTCTCTTCT3'

Genbank AF157015(31)

atpase forward

5'CAGGGGACAATCACAT3'

RAP-PCR sequence

atpase reverse

5'GCAGCATCAGTCTTCAT3'

RAP-PCR sequence

groEL forward

5'GCCTGGATTTGGTGAT3'

RAP-PCR sequence

groEL reverse

5'AGTTTCAGTGCCGCTAC3'

RAP-PCR sequence

groES forward

5'TGTCGGTGGTTTTGTTC3'

RAP-PCR sequence

groES reverse

5'ACCAGCACCATTTTCG3'

RAP-PCR sequence
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Company). GBS cpsE, scpB, and cyl PCR products were normalized against a 16S
product.
GBS Protein Isolation. GBS 2407 protein pellets snap-frozen in liquid nitrogen were
disrupted in protein lysis buffer (0.1 M Tris, pH 7.5; 0.5 M EDTA; glycerol; leupeptin (1
mg/ml); aprotinin (1 mg/ml); pepstatin (1 mg/ml); PMSF (17.4 mg/ml); PBS) using the
Mini-BeadBeater and 0.1 mm zirconia-silica beads for 3 minutes at 5000 rpm. The GBS
lysates were centrifuged at 14,000 x g for 10 minutes at 4°C to pellet cellular debris. The
supernatant was concentrated using Centricon YM-3 centrifugal filter devices (Millipore,
Bedford, MA) according to the manufacturer’s instructions. The protein concentration
was measured using the BCA Protein Assay kit from Pierce (Rockford, IL).
Western Blot Analysis. Eight micrograms of concentrated GBS protein lysate were
loaded onto a denaturing 4 –15% linear gradient Criterion polyacrylamide gel (BioRad,
Hercules, CA). The proteins were transferred to a 0.45 µm nitrocellulose membrane
(Stratagene, Cedar Creek, TX) by semi-dry electroblotting. Membranes were blocked
overnight at 4°C with Tris-buffered saline – 0.1% Tween 20 (TBS-T) plus 3% dry nonfat
milk. Blots were incubated with a 1:750 dilution of anti-GroEL polyclonal antibody
(StressGen Biotechnologies, Corp., Victoria, BC Canada) in TBS-T-milk for 1 hour at
room temperature, followed by 3 washes in TBS-T. Incubation with a 1:20,000 dilution
of goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (BioRad,
Hercules, CA) was followed by chemiluminescent detection using the SuperSignal West
Pico Chemiluminescent Substrate kit (Pierce).
Real Time PCR Standards. GBS 2407 virulence gene PCR products were cloned into
the pCR4.0-TOPO vector and transformed into TOP10 One Shot E. coli using the TOPO-
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TA Cloning Kit for Sequencing (Invitrogen, Carlsbad, CA).

Ampicillin-resistant

transformants were PCR-screened for the appropriate insert. An insert-positive colony
was then inoculated into LB broth with 50 µg/ml ampicillin and incubated with shaking
for 12-16 hours at 37°C. Plasmid DNA isolated using the Qiagen Plasmid Mini Kit was
used as template in PCR reactions as described above. The PCR products were separated
on a 2% NuSieve GTG – SeaKem GTG agarose gel containing GelStar nucleic acid stain
and then extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen). The
molecules of standard per microliter were calculated for the extracted DNA and serial
ten-fold dilutions ranging from 108 to 101 molecules/µl were made in nuclease-free water
(Promega Corporation). The standard dilutions were frozen at -20°C until use.
Real Time PCR. To quantify GBS 2407 virulence gene expression real time PCR was
performed using the iCycler Real Time PCR System (BioRad). All reactions included 1
µl standard DNA dilution or GBS cDNA in addition to standard reaction components and
3 µl of a 1:50,000 dilution of SYBR Green I nucleic acid stain (BioWhittaker Molecular
Applications). iCycler conditions were as described for the PCR reactions minus the
final 7 minute extension.

All standards were run in duplicate reactions and all

experimental samples were run in triplicate. Experimental sample mRNA copy number
was calculated from a standard curve using the iCycler Optical System Interface software
version 2.3 (BioRad).
Haptogobin real time PCR standards were prepared as described above for GBS
standards and reactions were conducted using haptoglobin gene-specific primers and
cycling conditions previously described by Piniero (29).
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Random Arbitrarily Primed–PCR (RAP-PCR). Two microliters of GBS cDNA were
added to PCR reactions and amplified using the Advantage cDNA Polymerase Mix
(Clontech, Palo Alto, CA) and pairs of random primers from the Delta Differential
Display Kit (Clontech). Cycling conditions were 94°C for 1 minute; 40 cycles of 94°C
for 30 seconds, 40°C for 2 minutes, 72°C for 30 seconds; followed by a final extension at
72°C for 10 minutes. RAP-PCR products were visualized on a 2% Metaphor agarose
(BioWhittaker Molecular Applications) containing GelStar nucleic acid stain in a
horizontal gel electrophoresis apparatus for 4 hours at 80 volts. A 100 bp step ladder
(BioWhittaker Molecular Applications) was used to size RAP-PCR products.
Differential expression of RAP-PCR products was verified by real time PCR as described
above using primers from Table 1.
Identification of Differentially Expressed Products. Differentially expressed bands
were extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen) and
reamplified using the same random primer set. Plasmid DNA isolated from TOP10 One
Shot E. coli transformed with pCR4.0 TOPO containing the PCR product was sequenced
by the Marshall University DNA Core Facility.

DNA sequence obtained from the

differentially expressed RAP-PCR products was compared to known bacterial genes and
genomes using the Basic Local Alignment Search Tool (1) (BLASTN and BLASTX
algorithms) provided on the National Center for Biotechnology Information website
(www.ncbi.nlm.nih.gov/BLAST/). The RAP-PCR sequence was then submitted to Dr.
Philippe Glaser and Dr. Frank Kunst at the Laboratoire de Genomique des
Microorganismes Pathogenes at the Institut Pasteur (Paris, France) to obtain the complete
gene sequence and surrounding sequences.
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Statistics. All statistical analyses were performed using SigmaStat (Jandel Scientific
Software, San Rafael, CA). Two-way analysis of variance was used for comparisons of
GBS growth measurements.

Student’s t-test was used for comparisons of gene

expression. Differences were considered statistically significant when P < 0.05.
RESULTS
Cytokine effects on GBS growth.

To determine the effects of proinflammatory

cytokines on its growth, GBS 2407 was incubated with concentrations of TNF-α, IL-1β,
or IL-6 ranging from 0-100 ng/ml for 8 hours. Optical density readings at 600 nm
revealed that GBS growth was significantly increased by exposure to 100 ng/ml IL-1β or
IL-6 (P < 0.05), while TNF-α had no effect at any concentration (Fig. 1). Because this
concentration of IL-1β was supraphysiologic, even for a septic state, potential synergistic
effects between IL-1β and IL-6 were evaluated. Figure 2 shows the results of incubation
of GBS with one cytokine concentration held at 10 ng/ml and the other varied from 0-100
ng/ml. An increase in GBS growth was only observed when the concentration of the
second cytokine was 100 ng/ml. This growth enhancement was not different from what
was observed for the individual cytokine treatments (Fig. 1) indicating that there was no
synergism between IL-1β and IL-6. These results suggested that only IL-6 is likely to
enhance GBS growth in vivo. Consequently, only the effects of IL-6 exposure on GBS
growth were further investigated.
A concern arose that perhaps this increase in GBS growth following IL-6
exposure was nonspecific and due to the bacteria’s use of IL-6 as a nutrient source. To
rule out this possibility the requirement for IL-6 biologic activity in enhancement of GBS
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FIG. 1. IL-1β and IL-6, but not TNF-α, increase GBS growth. GBS were incubated with
increasing concentrations of TNF-α (A), IL-1β (B), and IL-6 (C) at 37°C in 5% CO2.
GBS growth was monitored by optical density at 600 nm every hour for 8 hours. Twoway analysis of variance indicated a significant increase in GBS growth at 100 ng/ml IL1β or IL-6 (P < 0.05) versus growth with no cytokine.
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FIG. 2. IL-1β and IL-6 do not act synergistically to enhance GBS growth. GBS were
incubated with IL-1β at 10 ng/ml and varying concentrations of IL-6 (A) or with IL-6 at
10 ng/ml and varying concentrations of IL-1β (B). GBS growth was monitored by
optical density at 600 nm every hour for 8 hours. Two-way analysis of variance indicated
significant growth enhancement only occurred at IL-1β and IL-6 concentrations of 100
ng/ml (P < 0.05).
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growth was tested. Inactivation of IL-6 was accomplished by boiling for 20 minutes. To
verify inactivation of IL-6 biologic activity, confluent monolayers of HuH-7 liver
carcinoma cells were incubated with 0 ng/ml, 100 ng/ml, or 100 ng/ml inactivated IL-6
for 24 hours in 5% CO2 at 37°C. Real time PCR analysis was performed to examine the
IL-6-induced expression of haptoglobin, an acute phase reactant protein. The expression
of the haptoglobin gene was significantly decreased by the inactivation of IL-6 (P <
0.001) compared to expression induced by the untreated IL-6 (See Appendix C, Figure
1). When inactivated IL-6 was supplied in the media, the stimulation of GBS growth was
abolished indicating that IL-6 biologic activity is required for its enhancement of GBS
growth (Fig. 3). The necessity for biologically active IL-6 in the augmentation of GBS
proliferation implies that IL-6 functions as more than a nutritional source for GBS and
may influence additional bacterial characteristics including virulence properties.
IL-6 binding to GBS. Cytokines mediate their effects by binding receptors on the host
cell surface. We investigated IL-6 binding to GBS using flow cytometry. An increase in
bacteria-associated fluorescence after incubation of GBS with FITC-conjugated IL-6
indicated an interaction between GBS and IL-6 (Fig. 4). Treatment of the FITC-IL-6
with an anti-human IL-6 blocking monoclonal antibody prior to the incubation with GBS
decreased the fluorescence to the same level as the negative control thereby illustrating
the “specificity” of the interaction.
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FIG. 3. IL-6 biologic activity is required for enhancement of GBS growth. GBS were
incubated with 0 ng/ml, 100 ng/ml active, or 100 ng/ml inactivated IL-6. GBS growth
was monitored by optical density at 600 nm for 8 hours. Two-way analysis of variance
indicated that treatment with inactivated IL-6 was not significantly different from no IL-6
treatment. Asterisk indicates significant difference (P < 0.05) from both no IL-6 and
inactivated IL-6 treatment.
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FIG. 4. GBS binds IL-6. GBS incubated with FITC-conjugated IL-6 showed an increase
in fluorescence indicating binding of IL-6 to the bacteria. GBS incubated with FITC-IL6 pretreated with an anti-human IL-6 blocking antibody exhibited a fluorescence level
equivalent to that of the negative control indicating that binding was specific for IL-6.
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IL-6 effects on expression of GBS virulence factors. Ross et al (33) report that growth
rates alter expression of several GBS virulence factor genes. Because IL-6 increased
GBS growth, RT-PCR and real time PCR analyses of the effects of IL-6 exposure on the
mRNA expression of three GBS virulence factors (cytolysin, capsule polysaccharide, and
C5a peptidase) were performed. No difference in expression of the GBS cytolysin gene,
cyl, or of a capsule polysaccharide gene, cpsE, was observed in IL-6-treated GBS
compared to nontreated bacteria (See Appendix C, Figure 2). Expression of scpB, the
GBS C5a peptidase gene, was significantly increased after IL-6 exposure by RT-PCR
analysis (Fig. 5). These data indicate that elevated IL-6 concentrations may boost GBS’s
virulence.
RAP-PCR.

A more global investigation of the alteration of GBS gene expression

following IL-6 treatment was then conducted using RAP-PCR, a modification of
differential display PCR.

Four products showed increased expression upon IL-6

treatment. Results from DNA sequencing and BLAST comparisons revealed that the
products were homologous to genes encoding an ATP-binding protein (ATPase) of an
ABC transporter (Fig. 6), the DNA-dependent RNA polymerase β' subunit, an unknown
protein, the 23S rRNA subunit (data not shown). Of these four products the most
intriguing prospect for additional investigation was the ATP-binding protein because of
the important roles that ABC transporters play in bacteria, which range from import and
export of nutrients and wastes to antibiotic resistance to secretion of virulence factors.
In order to gain insight into possible functions for this ATPase and its associated
transporter, nucleotide sequence for the regions flanking the sequence represented by the
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FIG. 5. Expression of the GBS C5a peptidase gene (scpB) may be increased by IL-6
exposure. Total RNA was isolated from GBS incubated with or without 100 ng/ml IL-6.
Expression of scpB was analyzed by RT-PCR (A) and real time PCR (B). IL-6 exposure
increased scpB expression (P < 0.05 by Student’s t-test) by RT-PCR. The difference was
not statistically significant by real time PCR analysis.
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FIG. 6. RAP-PCR identified a 415 bp product that is upregulated upon GBS exposure to
100 ng/ml IL-6 for 8 hours. Lane 1 (M) is a 100 bp ladder used to estimate RAP-PCR
product size. Lanes 2 and 3 (-) represent GBS not exposed to IL-6, while lanes 4 and 5
(+) represent GBS exposed to IL-6.
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ATPase RAP-PCR product was obtained from the databases for the Streptococcus
agalactiae genome sequencing project (courtesy of Drs. Philippe Glaser and Frank Kunst
at the Institut Pasteur). A schematic of the 6.5 kilobases of DNA sequence surrounding
the ATPase gene is shown in Figure 7A. Directly upstream of the gene encoding the
ATP-binding protein are genes coding for two conserved proteins with unknown function
and a gene for an ABC transport permease. Downstream of the ATPase gene are the
genes of the GroE operon.
Real time PCR analysis of expression of the ATPase, GroES, and GroEL genes
was conducted (Fig. 7B, C, D). Expression of all three genes was significantly enhanced
in response to IL-6 (P < 0.05). Interestingly, the increase was approximately six-fold for
each when compared to that of untreated GBS.
Due to the similar pattern of gene expression upon IL-6 treatment, as well as the
proximity of the genes on the GBS chromosome, the possibility that the ATPase and
GroE genes form a single operon was examined.

Analysis of the DNA sequence

upstream of the predicted ABC transporter, between bases 880 and 1367, using Omiga
2.0 software (Accelrys, San Diego, CA) yielded only one reasonable candidate for
promoter sites (-35 site at bases 988-993 and –10 site at bases 1011-1016). Further
evidence that the genes of the ABC transporter and the GroE operon may constitute one
operon was that a single transcript incorporating the ATPase through GroEL was
identified by RT-PCR (Fig. 8) and verified by DNA sequencing. These data strongly
suggest that the ATPase and the GroE genes form a functional genetic unit.
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FIG. 7. DNA sequence and expression analysis of genes surrounding the ATPase gene.
(A) Schematic of DNA sequence surrounding the ATPase identified by RAP-PCR. The
arrows indicate the directionality of each gene. The expanded area represents the region
spanning bases 881 to 2308 of the 6.5kb DNA sequence segment. This expanded region
contains the –35 and –10 promoter sites (at bases 988-993 and 1011-1016, respectively)
for the transcript encoded by the downstream genes. (B-D) ATPase, GroES, and GroEL
mRNA expression are increased in IL-6-treated GBS. Total RNA isolated from GBS
treated with no IL-6 or 100ng/ml IL-6 was analyzed by real time PCR for expression of
ATPase (B), groES (C), and groEL (D). All three genes demonstrated a significant
increase in expression following IL-6 exposure for 8 hours (P < 0.05). (E) Western blot
analysis of GBS GroEL protein expression after IL-6 treatment for 10 hours. Lanes 1 and
2 represent the untreated GBS from two separate experiments, lanes 3 and 4 represent the
matching IL-6-treated GBS from the same experiments, and lane 5 is 10 ng of a positive
control GroEL protein. An increase in GroEL protein expression is seen when comparing
the IL-6-treated GBS to their respective untreated controls (lane 3 versus lane 1 and lane
4 versus lane 2).
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FIG. 8. RT-PCR analysis indicates that the genes encoding the ATPase, GroES, and
GroEL are transcribed as a single message. Lane 2 is a transcript spanning the ATPase
gene through the GroES gene and lane 3 is the corresponding negative control. Lane 4 is
a transcript spanning the ATPase gene through the GroEL gene and lane 5 is the
corresponding negative control. Lane 6 is a water control. Lane 1 is a 1Kb Plus DNA
Ladder (Invitrogen) which was used to verify the predicted sizes of the PCR products,
881 bp for ATPase-GroES and 2480 bp for ATPase-GroEL.
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Western blot analysis. To confirm that the increase in GroEL mRNA expression leads
to an increase in the protein levels, total protein lysates from IL-6 treated and nontreated
GBS were separated by denaturing polyacrylamide gel electrophoresis and GroEL protein
was detected by an anti-GroEL monoclonal antibody. Although GroEL mRNA from
GBS treated for 8 hours with IL-6 was increased, analysis of protein at this time period
did not show any difference in expression from nontreated GBS (See Appendix C, Figure
3).

However, GBS treated for 10 hours with IL-6 showed an increase in GroEL

expression compared to untreated GBS (Fig. 6E).
DISCUSSION
Environmental conditions greatly influence cellular/organismal responses. During the
initiation of an infection or during colonization, factors produced by both the host and the
microbe direct the outcome.

When the host’s immune system encounters potential

pathogens, a multitude of cytokines are secreted to instruct the host’s defenses on how to
eliminate the threat. Little is known about how this cytokine-enriched microenvironment
may directly affect the microorganism that prompted the immune response. For this
reason, we chose to examine the effects that pro-inflammatory cytokines generated in
response to group B streptococcus have on the bacteria’s growth and expression of
virulence.
The predominant cytokines secreted during GBS infection and sepsis are TNF-α,
IL-1β, and IL-6 (2, 22, 39). Incubation of a serotype III GBS isolate with increasing
concentrations of these three cytokines revealed that high concentrations of IL-1β and
IL-6 significantly enhanced bacterial proliferation (Fig. 1), but only the IL-6
concentration was within physiologic range. In addition, the increase in GBS growth in
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response to IL-6 exposure required IL-6 biologic activity (Fig. 3). Our data is not unlike
a number of other studies demonstrating that cytokines possess bacterial growth
promoting activity. These studies reveal that growth of virulent E. coli is increased by
exposure

to

interleukin-2,

granulocytes-macrophage

colony-stimulating

factor,

interleukin-1, and interferon-γ (7, 30), while M. avium growth is enhanced by exposure to
interleukin-6 and interleukin-1α (8). Likewise, others report that M. tuberculosis growth
is augmented by transforming growth factor-β (18); L. monocytogenes by colonystimulating factor-1, and interleukin-3 (9); and S. aureus by tumor necrosis factor-α,
interleukin-1β, and interleukin-6 (26).
Similar to data presented in the current study, Denis et al (7) observe that heatinactivation of interleukin-2 prevents its growth promotion of virulent E. coli. Luo et al
(24) report that binding of tumor necrosis factor-α to S. flexneri requires the cytokine’s
biologic activity. The necessity for cytokine biologic activity suggests that cytokines
may exert their effects on the bacteria in ways that may in fact alter the bacteria’s
virulence characteristics.
In the host, cytokines bind specific receptors in order to induce their effects. Our
data showed that IL-6 does in fact bind to GBS and that this binding can be blocked by an
anti-IL-6 monoclonal antibody (Fig. 4A). In other studies, binding interactions between
TNF-α and S. flexneri, S. typhimurium, and E. coli (24); IL-1β and S. aureus (20) and Y.
pestis (42); and interleukin-2 and C. albicans (38) have been observed. Binding of
cytokines to the bacterial surface again suggests that the cytokines may be responsible for
influencing the bacteria beyond the enhancement of bacterial proliferation. Perhaps, IL-6
is modulating GBS pathogenicity by binding a bacterial surface molecule that is
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associated with a two-component signal transduction system that initiates a phosphorelay
cascade involved in the activation of virulence expression (14, 19).
Because alterations in growth rates and cell densities (21, 40, 4, 25) are often
associated with changes in bacterial virulence characteristics, we initially chose three of
the most well-characterized GBS virulence factors (35) and analyzed their mRNA
expression in response to IL-6 exposure.

Of these, only the C5a peptidase gene

expression appeared to be upregulated by IL-6 exposure.

However, these results

suggested that other virulence factors or proteins may in fact be candidates for study.
To this end, RAP-PCR analysis of GBS gene expression in response to IL-6
treatment was conducted. The results indicated that expression of an ATPase of an ABC
transporter upstream of the GBS GroE heat shock proteins was significantly increased
(Fig. 6A). Real time PCR confirmed these data, as well as demonstrated that expression
of GroEL and GroES were also concomitantly increased (Fig. 6B, C, D). Western blot
analysis also showed an increase in GroEL protein levels in IL-6-treated GBS (Fig. 6E).
In addition to its association with the heat shock response, expression of GroEL
has more recently been correlated with pathogenesis in many bacterial species. For
example, GroEL shows increased expression upon contact with host cells in L.
pneumophila (13), L. monocytogenes (12), and M. tuberculosis (27). The GroEL protein
also appears to become surface-exposed and mediates attachment and/or internalization
to the host cells during infection with L. pneumophila (13), H. influenzae (16), S.
typhimurium (10), H. pylori (28), C. difficile (17), and H. ducreyi (11). In order for these
bacteria to use GroEL for attachment, the protein must translocate from the cytoplasm to
the bacterial cell surface. In C. difficile surface expression has been proposed to be via a
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type III secretion system or an ABC transporter (17), although no empirical evidence has
yet been reported. Genomic sequence analysis of the region surrounding the GBS
ATPase gene identified a single promoter region between the two conserved proteins
upstream of the ATPase gene. As no other potential promoter sites were recognized
within the sequence, it appeared that the ABC transporter containing the ATPase gene
and the GroE genes were part of one transcriptional unit. RT-PCR analysis revealed a
single mRNA transcript spanning the ATPase gene through the GroEL gene. Detection
of the GroE genes and the ABC transporter as one message suggests that GroEL may
become surface-exposed via an ABC transporter in GBS.
In summary, our data provide evidence that GBS exposure to high concentrations
of IL-6 may also induce a stress-associated response in the bacteria in reaction to an
environment that mimics an environment similar to that which would be encountered
during GBS neonatal sepsis. Based on results from this study we speculate that in infants
with GBS disease that the GBS GroEL protein may be upregulated and become surfaceexpressed.

Supporting this hypothesis, patients suffering from infections with B.

pseudomallei (41), L. kirschneri (15), C. trachomatis (34), and S. pyogenes (23) have
high antibody titers to the GroEL protein from the infecting bacterial species.
Current strategies for prevention of GBS disease center around the design of a
vaccine using immunogenic GBS surface proteins in conjunction with the serotypespecific capsular polysaccharides. Identification of factors upregulated in response to
cytokine exposure, or to an environment similar to that encountered in the host, may
uncover GBS proteins that could be included as conjugates in a GBS vaccine to boost the
vaccine’s efficacy.
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FIG. 1. Inactivation of IL-6 abolishes the IL-6-inducible expression of the haptoglobin
gene by HuH-7 cells. GBS was incubated with no IL-6, 100 ng/ml IL-6, or 100 ng/ml
inactivated IL-6 for 8 hours at 37°C.

Asterisk indicates that haptoglobin mRNA

expression at 100 ng/ml IL-6 is significantly different from that at 0 ng/ml IL-6 and 100
ng/ml inactivated IL-6 by Student’s t-test.
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FIG. 2. mRNA expression analysis of two GBS virulence factor genes, cyl and cpsE,
does not show an increase following IL-6 exposure.

(A) Expression of the GBS

cytolysin/hemolysin gene (cyl) is not increased by IL-6 exposure using RT-PCR (top) and
real time PCR (bottom). (B) Expression of the GBS capsule polysaccharide gene E
(cpsE) is not increased by IL-6 exposure using RT-PCR (top) and real time PCR
(bottom).
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FIG. 3.

The GBS GroEL protein does not show an increase in expression by

densitometric analysis after 8 hours of IL-6 exposure. Lanes 1-3 represent untreated GBS
from 3 separate experiments.

Lanes 4-6 represent IL-6-treated GBS from the

corresponding experiments. Lane 7 is 10 ng of a positive control GroEL protein.
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CHAPTER 5: GENERAL DISCUSSION
Group B streptococcus has emerged over the last 30 years as one of the primary
threats to infants during the first days and months of their lives. Thousands of neonates
are put at risk each year because their mothers carry this potential life-threatening
bacterium in the gastrointestinal and/or urogenital tract. Not only is GBS a major health
concern for obstetricians and pediatricians, but it can also place a significant financial
burden on the families of infected infants as well as the treatment facility. Since the mid1990’s emphasis on identifying women at risk, prophylactic treatment during pregnancy,
and design of a GBS vaccine has been the principal focus of both clinicians and
researchers alike. Although some research has studied immunity to GBS, knowledge
concerning the interactions of the human immune system with GBS remains limited.
Understanding these interactions would increase the likelihood of designing successful
therapeutic and preventative strategies.
During the time when a microorganism is trying to establish colonization or an
infection and the immune system is trying to thwart the microbe’s attempts, many
complex interactions take place. For a number of bacterial species, the fight for survival
involves evading destruction by using the host immune response to its own advantage.
For example, phagocytosis of bacteria that survive intracellularly within macrophages
can lead to the creation of a protective niche for the microbe within the immune system
itself.
We speculated that, like many other bacterial species, interactions between GBS
and the human immune system may contribute to colonization by GBS, or at least do not
result in the appropriate clearance of GBS. As phagocytosis by cells of the immune
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system is one of the earliest steps in host defense, we examined engulfment of GBS and
the respiratory burst activity subsequent to engulfment in phagocytes from GBScolonized and noncolonized women. We observed that monocytes from pregnant, GBScolonized women engulfed significantly greater numbers of GBS, while expelling the
superoxide (generated to kill the engulfed GBS) into the extracellular environment. This
would seem to support the notion that GBS is capable of turning the host’s immune
response to its own advantage. Internalization of GBS into the monocytes, in which the
antimicrobial defenses have been undermined, may create a protective niche for the
bacteria.

Further support that GBS may become sequestered within the

monocyte/macrophage as a haven for GBS comes from Valentin-Weigand et al (1996)
and Cornacchione et al (1998) whose work provides evidence that GBS survive
intracellularly for extended periods of time.
Phagocytosis of bacteria is enhanced by opsonization with bacteria-specific
antibodies, complement components, or lectins. Numerous studies have demonstrated
that the most effective opsonins for enhancing GBS clearance are antibodies to the
serotype-specific capsule polysaccharide (Baker et al, 1976; Shigeoka et al, 1978;
Kallman et al, 1998; Campbell et al, 2000) and components of the classical complement
pathway (Shigeoka et al, 1978). However, most individuals fail to produce sufficient
quantities of anti-capsular antibodies after natural infection (Baker et al, 1976) or
vaccination (Baker et al, 1988). Even in the absence of antibody opsonization and
activation of the classical complement pathway, the alternative pathway should be
activated but is not in response to GBS because of bacteria’s high sialic acid content
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capsule. Little is known regarding the interaction between GBS and the final opsonic
pathway for enhancement of phagocytosis, the lectin pathway.
We originally hypothesized that GBS colonization was associated with a
deficiency in one of the lectin pathway components, mannose binding lectin. Initial data
(Smith et al, 2001) demonstrating that a greater number of GBS-colonized women carried
variant alleles for the first exon of the MBL gene, which have been associated with serum
MBL deficiencies, supported this hypothesis.
subjects this association disappeared.

However, with the addition of more

Additionally, no association between GBS

colonization status and polymorphisms in the MBL gene promoter was observed. We
anticipated that measurement of MBL concentrations from sera of GBS-colonized and
noncolonized women would reflect the genetic findings.

Interestingly, the GBS-

colonized women had significantly higher levels of MBL in their sera compared to
noncolonized women.
Based on the results of the MBL serum ELISAs, we realized that perhaps our
initial hypothesis concerning GBS colonization association with MBL deficiency was the
opposite of what was really occurring. We focused our efforts on investigating the
possibility that MBL may function in mediating phagocytosis of GBS in the absence of
specific antibody.

To evaluate this hypothesis, we conducted additional phagocytic

engulfment assays using serum with a known concentration of MBL as the opsonin
source. Our data revealed that at high concentrations of MBL, uptake of GBS was
increased. However, a decline in engulfment at lower concentrations of MBL suggested
that there is a threshold level required for enhancement of GBS engulfment by human
phagocytes. These results would appear to be in conflict with Van Emmerik et al (1994)
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and Neth et al (2000) who report that MBL demonstrates little binding to GBS and that
this low level of binding is not sufficient to make MBL an efficient opsonin for GBS.
However, neither group examines phagocytosis to determine whether or not this level of
binding to GBS can act as opsonization in a functional phagocytosis assay. Also, there is
no indication as to the concentrations of MBL used in their binding assays and therefore
it may have been below the threshold for enhanced uptake that we observed. It appears
that higher levels of MBL may be needed to initiate opsonization with an organism like
GBS that is highly encapsulated.
Our data from previous engulfment experiments, taken with the results of the
MBL phagocytosis experiments, suggest that high concentrations of MBL in the sera of
GBS-colonized women may lead to the increased engulfment of GBS by phagocytes
from these women and that internalization by this pathway could facilitate the creation of
a protective niche for GBS within the immune system.
One of the major events following phagocytosis of a microbe is production of
cytokines that function to activate a variety of effector cells that initiate inflammation as
well as the antigen-specific immune response. There are three primary pro-inflammatory
cytokines, TNF-α, IL-1β, and IL-6. These are secreted by the human immune system in
response to GBS or various parts of the bacterium (De Bont et al, 1993; Williams et al,
1993; Peat et al, 1994; Vallejo et al, 1996; Von Hunolstein et al, 1997; Kwak et al, 2000;
Berner et al, 2001). Because these cytokines can be found at high concentrations in the
circulation of infants with GBS sepsis we were interested in investigating what effects
these cytokines might have on GBS. Other studies have shown that cytokines enhance
the growth and virulence characteristics of a variety of bacterial species (Denis et al,
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1991; Denis and Gregg, 1991a; Denis and Gregg, 1991b; Porat et al, 1991; Hirsch et al,
1994; Meduri et al, 1999; Kanangat et al, 2001). Our data indicated that, of the three proinflammatory cytokines we tested, only IL-6 significantly enhanced GBS growth at a
concentration that is physiologically relevant. We also determined that IL-6 biologic
activity was required for its growth promoting characteristics. Similarly, Denis et al
(1991) and Luo et al (1993) show that the biologic activity of IL-2 and TNF-α are
necessary to exert their effects on E. coli and S. flexneri, respectively. We speculate that
the requirement for the cytokine’s biologic activity in enhancing GBS growth indicates
that IL-6 may function as a signal for the bacteria that induces alterations in GBS
virulence characteristics.
By using IL-6 to enhance its growth, GBS is again using the host’s own
machinery for its own benefit. IL-6 not only increases the bacterial load that the host
must respond to, but may also decrease the availability of IL-6 for the host’s own use.
Other bacterial species, including S. flexneri (Luo et al, 1993), S. aureus (Kanangat et al,
2001), Y. pestis (Zav’yalov et al, 1995), bind host cytokines thereby potentially impairing
the host’s signaling pathways for activation of key effector mechanisms.

We

demonstrated that GBS binds to IL-6 and that this binding increases as the concentration
of IL-6 is increased (Appendix D, Figure 1). We also demonstrated that the binding of
GBS to IL-6 is a low affinity interaction based on the slow decline in IL-6 binding
observed when unlabeled IL-6 was added as a competitor for the IL-6 binding site on the
bacterial surface (Appendix D, Figure 2). The exact molecule on the GBS cell surface
that interacts with IL-6 has yet to be identified. To date only the Caf1A usher protein of
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Y. pestis has been identified as a surface protein that binds a host cytokine, IL-1β
(Zav’yalov et al, 1995).
As a way of approaching whether or not the IL-6 GBS interaction affects GBS
virulence other than by increasing bacterial proliferation, we examined the gene
expression of three of the most studied GBS virulence factors (the cytolysin, the capsule
polysaccharide, and the C5a peptidase). Of the three virulence factors examined only
one, the C5a-ase, showed an increase in mRNA levels following an eight-hour exposure
to IL-6 and this increase was only detectable by RT-PCR analysis. It is possible that
expression of these factors may be upregulated at other times after exposure. However,
this is unlikely because the virulence factors produced by other bacteria are induced in
the late exponential or stationary phases of growth (Chan et al, 1998; Winzer et al, 2001)
similar to the point in the GBS growth cycle after 8 hours.
Because additional factors may be induced in response to IL-6 treatment of GBS,
we took a global approach at examining induction of gene expression using random
arbitrarily primed PCR. Of the four products we identified as being upregulated in
response to IL-6, the most intriguing was the gene coding an ATP-binding protein that is
associated with an ABC transporter. ABC transporters in bacteria function in many
capacities including import and export of molecules involved in cellular metabolism,
antibiotic resistance, and secretion of virulence factors (Higgins, 2001). Analysis of the
genomic sequence surrounding this ATPase gene revealed that it was upstream from the
GroES and GroEL genes. Real time PCR data indicated that not only was ATPase gene
expression upregulated in response to IL-6, so was expression of the GroES and GroEL
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genes. Western blot analysis also revealed that the increase in GroEL mRNA levels leads
to an increase in GroEL protein.
The GroE proteins are heat shock proteins that are responsible for ensuring the
proper folding of proteins that are destined to be secreted from the cell (Brocchieri et al,
2000). The GroEL protein has also been implicated in the pathogenesis of other bacterial
diseases. The GroEL protein of C. trachomatis appears to be the antigen responsible for
the delayed-type hypersensitivity response associated with chlamydial infections
(Sanchez-Campillo et al, 1999). GroEL protein levels are increased upon contact with
host cells or entry into macrophages by L. pneumophila (Garduno et al, 2001), L.
monocytogenes (Gahan et al, 2001), and M. tuberculosis (Monahan et al, 2001). GroEL
has also been identified as a mediator of attachment to host cells by L. pneumophila
(Garduno et al, 2001), H. influenzae (Hartmann et al, 1997), S. typhimurium (Ensgraber
et al, 1992), H. pylori (Phadnis et al, 1996) and C. difficile (Hennequin et al, 2001).
The increase in GroEL gene expression in GBS exposed to IL-6 suggests that
IL-6 is capable of inducing a stress response in GBS that in some manner is similar to
that which it would encounter in the host environment. Further investigation of the role
of GroEL in the pathogenesis of GBS is warranted.
While there is still a great deal to learn concerning the virulence of group B
streptococcus, the data presented here sheds some light on basic interactions between the
host innate immune system and GBS. We have demonstrated that some components of
the host immune defenses that should function to protect the host against GBS
colonization or infection may actually contribute to the process. A clearer picture of
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these host-bacteria interactions will assist in identifying additional targets for therapeutic
and preventative strategies for GBS.
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APPENDIX D. ADDITIONAL FIGURES FOR CHAPTER 5
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FIG. 1. An increase in GBS binding is observed as the concentration of FITC-IL-6 is
increased. GBS was incubated with increasing concentration of FITC-IL-6 ranging from
0 – 20 ng prior to detection of binding by flow cytometry. From this curve, 10 ng FITCIL-6 was used in the experimental binding assays.
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FIG. 2. Competition for the GBS IL-6 binding site between FITC-IL-6 and unlabeled
IL-6 reveals that the interaction has low affinity. GBS was incubated with 10 ng FITCIL-6 and concentrations of unlabeled IL-6 from 0 – 100 ng for 8 hours prior to detection
of binding by flow cytometry. Error bars represent the range of values from two separate
experiments.
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